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Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous 
system (CNS). Even though it is considered to be a classical demyelinating disease, an 
increasing body of evidence also demonstrates the early presence of inflammatory lesions in 
the grey matter. In experimental autoimmune encephalomyelitis (EAE), the animal paradigm 
of MS, preferential involvement of grey matter is rarely reported, hindering the study of this 
important aspect of the disease.   
In this thesis, green fluorescent protein (GFP)-transduced effector T cells reactive either 
against a myelin antigen, i.e. the myelin basic protein (TMBP-GFP) or against a neuronal 
antigen, i.e. the -synuclein (Tβ-Syn-GFP) were used to induce EAE by passive transfer in 
recipient Lewis rats. The aim was to elucidate the homing behaviour of encephalitogenic 
effector T cells into the distinct milieus of the CNS. Both of these T cell lines had a similar 
phenotype in vitro and similar pathogenic potential in vivo. However, they displayed a 
completely different infiltration pattern in the CNS tissue: whereas the TMBP-GFP cells were 
distributed mainly in the white matter, the Tβ-Syn-GFP cells were mostly located in the grey 
matter of the brain and spinal cord (SC), mimicking the cortical pathology of MS. This 
divergent infiltration pattern was not due to tissue-intrinsic properties such as apoptosis rate 
or chemokine expression in the different CNS compartments. Neither did cell-specific 
properties such as chemokine/integrin expression profile, cytokine level or T cell homing 
during the preclinical phase play any role. By using two–photon laser scanning microscopy it 
was possible to visualize in real time the entry and the distribution of TMBP-GFP cells and Tβ-Syn-
GFP cells in the meningeal compartments of brain and SC, thus providing indirect evidence 
that the antigen availability in the target tissue determines the level of activation and therefore 
the pattern of tissue invasion. Finally, direct activation of TMBP cells in the white matter and of 
Tβ-Syn cells in the grey matter of the CNS parenchyma was demonstrated in situ by using a 
genetically encoded NFAT (nuclear factor of T cell activation) biosensor further confirming 
that the antigen-dependent activation of encephalitogenic T cells is the key factor that 










1.1 The central nervous system: an immune privileged organ? 
For a long time the central nervous system (CNS) was thought to be an immune privileged 
tissue due to its molecular and cellular protection by the blood-brain barrier (BBB), the lack 
of lymphatic vessels and classical antigen presenting cells (APCs) within the tissue and a 
limited expression of constitutive MHC I and II molecules on CNS parenchymal cells 
(Engelhardt and Ransohoff, 2005). Today it is known that under physiological conditions the 
CNS is under immune surveillance. Beside resident microglia within the CNS parenchyma, 
peripheral immune cells assess the milieu in specialized compartments of brain and spinal 
cord (SC) outside the parenchyma (Ousman and Kubes, 2012). Moreover it is known that 
there is an immune cell subset that is able to express and carry specific molecular keys in 
response to pathological conditions, like multiple sclerosis (chapter 1.2) or its model 
experimental autoimmune encephalomyelitis (chapter 1.3), which enables specialized 
leukocytes to overcome the BBB and to infiltrate massively into the CNS (Engelhardt and 
Ransohoff, 2005). 
 
1.1.1 Meninges and the blood-CNS barriers  
The mammalian CNS is covered by three connective tissue membranes, named the meninges. 
Under the outermost meningeal layer, the dura mater, the adherent arachnoidea forms 
trabeculae which reach through the subarachnoidal space to the pia mater, the deepest layer of 
the meninges, which is adherent to the parenchymal basal membrane (fig. 1.1). Furthermore, 
the basement membrane and astrocytic end feet, together form the glia limitans, another 
border to the brain parenchyma (Ransohoff and Engelhardt, 2012). The arachnoid mater and 
the pia mater together are called leptomeninges. The leptomeninges contain the 
subarachnoidal space filled with the cerebrospinal fluid (CSF) and blood vessels that are build 
up by highly specialized endothelial cells, which are stably interconnected by tight junctions 
(fig. 1.1 and 1.2) (Engelhardt and Ransohoff, 2012). The pia mater encloses pre- and post-
capillary venules reaching down deeper into the brain parenchyma (fig. 1.1). Here, the 
parenchyma is segregated from the brain by the glia limitans establishing the deeper 
perivascular space, which is called Virchow-Robin space (fig. 1.1 and 1.2) (Gerhardt and 




As described above, the CNS is structurally separated from peripheral milieu by a diffusion 
barrier formed by tightly connected endothelial cells and the glia limitans, which together 
build up the BBB. Another protective barrier of the CNS, the blood-cerebrospinal fluid barrier 
(BCSFB), established by choroid plexus epithelial cells, is localized in the ventricular system 
of the brain. Here, tight junctions between these epithelial cells form a diffusion barrier 
(Engelhardt and Ransohoff, 2012). Together those barriers maintain a stable environment and 
homeostasis for the neurons and only selective transporters and ion channels mediate a blood-
brain concentration gradient and supply CNS cells with required metabolites (Pardridge, 
2003). Besides inhibiting uncontrolled trans-cellular molecular diffusion, the BBB establishes 





Figure 1.1 Schematic representation of the different anatomical levels from the meniges to brain or SC 
parenchyma. Under the dura mater and the arachnoidea, superficial leptomeningeal blood vessels lying on the 
surface of the brain and SC are directly surrounded by the CSF-filled subarachnoidal space. In contrast to deeper 
vessels, these vessels are not enveloped directly by the astrocytic end feet. Underneath, the subarachnoidal space 
is sealed by the pia mater and the glia limitans. Post-capillary venules and capillaries reach down into the brain 








Figure 1.2 Anatomy of the blood-brain barrier. Post-capillary venules and capillaries reach down into the 
parenchyma of the brain and SC. Their highly specialized endothelial cells (red) show a low pinocytic activity 
and are connected by tight junctions. The endothelial cells produce an endothelial basement membrane (yellow), 
which contains pericytes (pink). The basement membrane of postcapillary venules is surrounded by the 
perivascular space containing cerebrospinal fluid and phagocytes that are supposed to be antigen presenting cells 
(blue). The capillary basement membrane is directly associated with the glia limitans perivascularis composed of 
astrocytic end feet (green) and the parenchymal basement membrane (orange). Together, these described 
structures protect the underlying parenchymal neurons (grey). Modified from (Engelhardt and Ransohoff, 2012). 
 
 
1.2 Multiple sclerosis 
1.2.1 Multiple sclerosis: a short introduction 
Multiple sclerosis (MS) is the most common inflammatory disease of the central nervous 
system. The detailed pathomechanisms underlying MS are unknown, but the body of evidence 
strongly supports the hypothesis that MS is an autoimmune T cell-mediated disease (chapter 
1.2.5, 1.3.1 and 1.3.2). As the name of the disease indicates, multiple focal inflammatory 
infiltrates and demyelinating plaques can be found in the CNS of MS patients. These lesions 
are located in the brain, especially in the periventricular white matter (WM) (classically 
described MS lesions), cerebellum, brainstem and optic nerve (Pierson et al., 2012). 
Additionally, many patients develop lesions in the spinal cord (Thorpe et al., 1996; Nociti et 
al., 2005). Today it is known that the grey matter is involved in lesion formation as well and 




symptoms of a patient depend on the affected CNS areas. At disease onset symptoms like 
impaired vision, due to optic neuritis, and deficits in sensation are present. Later in the disease 
course sensory impairment is accompanied by paresis and paralysis, ataxia, fatigue, spasticity, 
cognitive impairment and incontinence (Baranzini et al., 2009). 
  
1.2.2 Epidemiology and clinical phenotypes 
The worldwide prevalence of MS can only be estimated and might be in a range between 1.1 
and 2.5 million cases. Geographically, areas with the highest frequency for MS are Western 
and Northern Europe, Canada, Russia, Israel, northern parts of the US, New Zealand and 
South and East Australia (Pugliatti et al., 2002; Barnett et al., 2009). People living near the 
equator are less affected (Compston and Coles, 2008). MS typically occurs in early adulthood 
and affects more often women than men.  
The disease course is very heterogeneous. Classically, MS is classified into 3 subtypes: 
Relapsing-remitting (RR), secondary progressive (SP) and primary progressive (PP). 80-90 % 
of patients start with a RR disease course, which is characterized by the recovery of 
physiological functions between the relapses (Bielekova and Martin, 2004; Miller, 2004). 
CNS lesions of these patients are often characterized by disturbance of the BBB, local 
oedema and demyelination (Miller et al., 1998). Over time (sometimes several years) most 
RR MS patients develop a SP disease. In this phase the recovery from symptoms decreases 
and patients retain progressive neurological deficits. Only 10-20 % of patients start with a PP 
disease course without acute relapses. These patients show less inflammation in the CNS and 
more severe axonal loss at earlier time points in the disease (Bashir and Whitaker, 1999; 
Leray et al., 2010). 
 
1.2.3 Histopathology 
The disease course of MS is variable in individuals. Moreover, MS lesions show a wide range 
of histopathological features in different patients. The analysis of active demyelinating lesions 
reveals reduced density of myelinated fibres and irregular ensheathment of axons. Four basic 
pathologic types of active WM demyelinating lesions in MS subtypes were described 
(Lucchinetti et al., 2000). All four lesion types show inflammatory infiltrates of T cells and 
macrophages. Furthermore, in the type I lesion activated macrophages and microglia were 
found to be associated with degenerating myelin (Lucchinetti et al., 2000). Here, the toxic 




type II lesion is very similar to lesion type I but additionally shows deposits of antibodies and 
active complement which may mediate demyelination. In type III lesions distal 
oligodendrogliopathy might lead to demyelination and in lesion type IV demyelination may 
take place as a reaction to primary oligodendrocyte damage (Lucchinetti et al., 2000). 
  
1.2.4 Cortical lesions in MS  
1.2.4.1 Cortical lesions in MS: an introduction 
For a long time MS was described as a disease which is primarily affecting the white matter 
of the central nervous system. The role of cortical grey matter lesions in the disease pathology 
was not in the focus of MS research. A disadvantage in former days was that the conventional 
histological methods and later the classical magnetic resonance imaging (MRI) technique did 
hardly allow the visualization of cortical lesions.  
Today, cortical grey matter lesions in MS are becoming an important field of research again. 
Improved pathological investigative procedures and MRI techniques, like high field MRI, 
allow to detect lesions in the grey matter of the brain and SC during in and ex vivo studies 
(Kidd et al., 1999; Bozzali et al., 2002). These studies show that cortical demyelinating 
lesions are all but rare. Additionally, the correlation of medical imaging methods and clinical 
parameters showed that grey matter lesions are related to the disabilities in MS patients and 
important indicators for the prognosis of disease development (Rovaris et al., 2006; Fisniku et 
al., 2008).  
Today the pathological classification of cortical lesions as defined by Peterson et al. is widely 
accepted (Peterson et al., 2001). Cortical demyelinating lesions can be divided in 4 
pathological lesion types. 
  
1. The type I lesion is named leucocortical lesion. It extends from deeper cortical grey 
matter layers into white matter regions. The superficial cortical layers are not 
involved.   
2. The type II lesion is called intracortical lesion. These lesions are small in size and 
they are limited in their expansion. They can only be found within the cortex and they 
are often in close proximity to blood vessels. The superficial cortex and the white 
matter are not involved. 
3. Type III lesions reach from the pial surface into the more superficial cortical layers. 




4. Type IV lesions extend through the whole cortical layers, but do not involve 
subcortical white matter areas.   
Type III and IV lesions are also called sub-pial lesions. 
 
Cortical damage can be found in the early disease and in further progressed stages. 
 
1.2.4.2 Cortical demyelination in early MS 
It is largely accepted that cortical lesions can be secondary to white matter damage due to 
retrograde degeneration (Simon et al., 2000; Cifelli et al., 2002). However, recently MRI and 
histological studies have challenged this classical view proposing that the cerebral cortex may 
represent an onset/early target of the disease process at least in a part of MS patients (Popescu 
and Lucchinetti, 2012). By using the latest MRI techniques it was shown that cortical lesions 
are present in 64 % of patients with RR MS and 70 % of patient with SP MS, but also in 37 % 
of patients with clinical isolated syndrome (Calabrese et al., 2007). Moreover, some MS 
patients exhibited cortical lesions and atrophy months/years before the MRI evidence of 
inflammatory lesions in the WM (Calabrese and Gallo, 2009). Also histopathological data 
evidence that early cortical demyelination and BBB damage can occur before the appearance 
of WM pathology or in no anatomical association with WM lesions (Bø et al., 2007; 
Lucchinetti et al., 2011; Popescu et al., 2011). These cortical lesions detected in 40 % of 
patients in early-stage MS showed, beside a reduction of oligodendrocyte density, a high level 
of inflammation that argues against a primary degenerative process at least in this early 
disease state (Lucchinetti et al., 2011). Myelin-laden macrophages and lymphocytes (mainly 
T cells), also a typical sign of active demyelinating WM lesions, can be found in affected 
areas (Lucchinetti et al., 2011; Popescu et al., 2011). These cells are often in close proximity 
to neurons and their processes indicating that these cells might directly promote neuronal 
damage (Lucchinetti et al., 2011; Popescu et al., 2011). Several examined cortical lesions 
from biopsies of early MS patients show neuritic swelling as a sign for acute neuronal damage 
(Lucchinetti et al., 2011). In early MS cortical demyelinated plaques were spatially associated 
with meningeal inflammation. This was shown especially for the sub-pial lesion type 





1.2.4.3 Cortical demyelination in chronic MS  
Neuropathological studies focusing on PP and SP MS patients show that cortical 
demyelinating lesions are numerous and wide spread events (Bø et al., 2003b; Kutzelnigg et 
al., 2005). Similar to cortical lesions in early MS these lesions were predominantly detected at 
the depth of the cerebral sulci. The affected areas are the cingulate gyrus, the frontal temporal 
insular and cerebellar cortices as well as the hippocampi. The paracentral lobule and the 
occipital lobes of the brain are less often affected (Huitinga et al., 2001; Bø et al., 2003b; 
Kutzelnigg et al., 2005; Geurts et al., 2007; Gilmore et al., 2009; Papadopoulos et al., 2009) 
(Choi et al., 2012). 
The pathological features of the cortical lesions of chronic MS patients are well-defined and 
consist of oligodendrocyte and neural damage, as well as loss of these cells (Peterson et al., 
2001; Bø et al., 2003a; 2003b; Wegner et al., 2006; Choi et al., 2012). Interestingly, cortical 
demyelinating lesions of progressive MS patients are generally less inflammatory than white 
matter lesions and grey matter lesions of early MS patients. Compared with previously 
mentioned lesions they show a very limited number of lymphocytes and macrophages. 
Furthermore, there is a lack of complement and immunoglobulin deposition (Peterson et al., 
2001; Bø et al., 2003a; 2003b). Ramified microglia cells can be detected in close proximity to 
neurons (Peterson et al., 2001; Bø et al., 2003a; 2003b). In contrast to the cortical lesions, the 
meninges of further progressed MS patients show inflammatory infiltrates. These infiltrates 
are associated with sub-pial lesions (Serafini et al., 2004; Magliozzi et al., 2007; Choi et al., 
2012). 
 
1.2.5 MS etiopathogenesis: the autoimmune hypothesis 
The described diversity in disease course, lesion localisation and symptoms as well as 
immunopathological appearance of these lesions may contribute to the fact that the cause of 
MS and the pathomechanisms are still under discussion. However, even if the formal proof is 
still lacking there are several lines of evidence that support the hypothesis that MS is an 
autoimmune T cell-mediated disease with secondary demyelination and tissue damage. 
As described in chapters 1.2.3 and 1.2.4, recent MS lesions, both in grey and white matter, are 
characterized by a massive infiltration of immune cells (mainly T cells) and 
monocytes/macrophages. It seems reasonable to assume that an immune reaction against CNS 
antigens can play a major role.Epidemiological studies emphasized the role of a genetic 




individuals (Dyment et al., 2006; Hemminki et al., 2009). Genome-wide association studies 
(GWAS) demonstrated that variations in the human leukocyte antigen (HLA) alleles are the 
main risk factor associated with the susceptibility to MS (International Multiple Sclerosis 
Genetics Consortium et al., 2007). In addition to the HLA locus, other susceptibility loci have 
been identified: among these loci, immunologically relevant genes, in particular T helper cell 
differentiation genes, are over-represented (International Multiple Sclerosis Genetics 
Consortium et al., 2011). In humans potential auto-reactive CD4
+
 T cells are known to be part 
of the normal T cell repertoire (Martin et al., 1992; O'Connor et al., 2001). When these cells 
by still unknown means become activated in the peripheral lymph nodes, for example by a 
cross reaction with foreign antigens such as viral peptides (molecular mimicry), they can 
clonally expand, circulate through the body and accumulate in the CNS (Hemmer et al., 
2002). These cells may be pathogenic as shown by experiments with non-human primates 
(Meinl et al., 1997) and with “humanized” transgenic mice (Madsen et al., 1999). Finally, 
immunotherapy targeted to T cells as well as to other immune cells (i.e. VLA-4 or CD52 
monoclonal antibodies) had significant effects on MS patients (Hohlfeld and Wekerle, 2004). 
Taken together, it appears that the human immune repertoire contains myelin-reactive T cells 
that can undergo clonal expansion and have encephalitogenic potential. These findings 
however do not clarify the specific contribution of these myelin-specific T cells to the 
pathogenesis of the disease. Our knowledge regarding this point is based on fundamental 
observations made in animal models of experimental autoimmune encephalomyelitis (EAE). 
 
1.3 Experimental autoimmune encephalomyelitis 
1.3.1 The history of experimental autoimmune encephalomyelitis 
The concept of MS being an autoimmune disease is strongly based on the animal paradigm of 
MS, the experimental autoimmune encephalomyelitis (EAE) (Freund and McDermott, 1942; 
Ben-Nun et al., 1981; Gold et al., 2006; Owens, 2006). In 1928 the first indication that an 
immune reaction against CNS components leads to brain inflammation was presented by 
Rivers who investigated epidemics of paralysis in people after vaccination against rabies 
(Remlinger, 1928; Baxter, 2007). In 1933/35 experimental animals were actively immunized 
with brain tissue to analyse the ascending paralysis previously seen in vaccinated people in 
more detail (Schwentker and Rivers, 1934; Rivers and Schwentker, 1935). It was discovered 
that the immunisation leads to the induction of inflammatory demyelinating lesions in the 




an emulsion consisting of lyophilised Mycobacterium tuberculosis and paraffin oil used to 
boost immune responses in the recipient animal, led to the development of the animal model 
EAE (in this form called active EAE: aEAE)(Freund and McDermott, 1942). 
Today it is known that EAE can be induced in a variety of animals (rabbits, rodents, monkeys 
etc.) by active immunisation with myelin antigens and CFA (Olitzky and Yager, 1949; Lipton 
and Freund, 1952; Genain et al., 1995). The course of disease and the severity of symptoms 
are species- and strain-dependent. The classical antigen shown to evoke EAE was myelin 
basic protein (MBP). Furthermore, other myelin antigens like myelin oligodendrocyte 
glycoprotein (MOG), proteolipid protein (PLP), and non-myelin antigens (for example S-
100β, a glia-specific protein expressed primarily in astrocytes) induce EAE as well (Linington 
et al., 1988; Piddlesden et al., 1993; Kojima et al., 1994; Kaye et al., 2000).  
The direct link that EAE is mediated by immune cells came from a study in which lymph 
node cells of immunized animals were used to transfer EAE to other animals (Paterson, 
1960). Another striking finding was that brain-specific CD4
+
 T cells are able to mediate EAE 
in healthy animals. In detail, lymphocytes from immunized animals were cultured under 
conditions favouring the CD4 T cell type. After purification the activated MBP-specific CD4
+
 
T cells were passively transferred into healthy syngeneic recipient animals, which developed 
a classical EAE after a defined time interval after transfer (Ben-Nun et al., 1981). The newly 
developed procedure was named passive transfer EAE (ptEAE). In early studies of EAE the 
general view was that TH1 cells, characterized by the production of IFN-γ, are the main 
players in EAE (Baron et al., 1993; Segal and Shevach, 1996; Liblau et al, 1995). Later the 
IL-17-producing T cell population, named TH17 cells, were recognized to be important in the 
induction of EAE as well (Cua et al., 2003; Langrish et al., 2005; Zepp et al., 2011). 
 
1.3.2 Passive transfer experimental autoimmune encephalomyelitis in the Lewis rat 
In the ptEAE model in Lewis rats, encephalitogenic MBP-specific TH1/TH17 T cells, which 
are able to infiltrate the CNS, are used to induce the disease (Wekerle, 2008). A big advantage 
of this approach is, that antigen-specific T cells can be generated in vitro and retrovirally 
engineered to express fluorescent proteins like green-fluorescent protein (GFP) (Flügel et al., 
1999). After stable integration of the GFP expression cassette into the genome, the protein is 
continuously expressed without interfering with T cell function (Flügel et al., 2007). The 
persistent labelling of these T cells (TMBP-GFP) allows their tracking and their functional 
characterization in the different compartments during all the disease phases (Flügel et al., 




technique into the immunological field, the fluorescently labelled encephalitogenic T cells can 
be also visualized and tracked in microanatomical environments, like the leptomeningeal 
areas of the CNS. 
 
1.3.3 Two-photon laser scanning microscopy: A tool to study T cell motility behaviour in 
situ  
To visualize and analyse the motility behaviour of effector TMBP-GFP cells within the meninges 
or the SC in real-time the technique of 2P-LSM has been used previously (Kawakami et al., 
2005a; Bartholomäus et al., 2009). 2P-LSM can be used to scan meningeal CNS tissue in all 
spatial directions. The generated Z-stack can be used to generate 3-dimensional pictures. If 
scanning of Z-stacks is performed over time 4-dimensional movies can be generated. 
Compared with conventional linear microscopy the main advantage of 2P-LSM is that a long-
waved laser in near-infrared range (700-980 nm) can be used. The usage of this long-waved 
laser allows a deeper penetration into the CNS tissue due to reduced scattering of the beam. 
Moreover, the lower energetic light of this laser induces lower phototoxic damage to the 
tissue compared to short wave length lasers (Helmchen and Denk, 2005). Therefore, this 
technique allows the imaging of pathophysiological processes in living animals over extended 
time periods without interfering with endogenous processes. As well known, due to the 
inversed correlation between wavelength and its energy, waves of long wavelength have 
lower energy. Therefore, to reach the energetic level necessary to excite the common 
fluorophores the two-photon effect is used. This effect that is generated by femtosecond-
pulsed lasers takes place when two (or more) photons arriving almost simultaneously at the 
focal point combine their energy to excite the fluorophore (Denk et al., 1990; Helmchen and 
Denk, 2005). The excitation of the fluorescent molecules is limited to the meeting point of the 
two photons, which also defines the area of emission. Hence, there is no emission from other 
areas and tissue layers beside the focal point of excitation (see fig. 1.3). Of consequence 














Figure 1.3 Comparison of conventional confocal (left side) and two-photon laser scanning microscopy (2P-
LSM) (right side). (A), top row: The upper panel shows the single photon excitation of a confocal microscope 
on the left side. Here, a fluorochrome is excited by an energy-rich (low wave-length) single photon. Thereby an 
electron transitions to an excited state from which it subsequently relaxes to energetic ground level. Thereby a 
part of the energy disperses and the other is converted in emitting fluorescence of higher wave-length light. On 
the right side, two photons with half of the energy and twice of the wave-length combine their energy by 
simultaneous absorption to excite an electron of a fluorochrome. (A), bottom row: During confocal microscopy 
tissue outside the focus point is also exposed to the high energetic light (black triangles). During 2P-LSM, the 
two- photon effect occurs only at the focus point at the focus plane (black circle). (B) During confocal 
microscopy the emitted light generated outside the focus point has to be blocked by a pinhole to detect only the 
light from the focus point.  In 2P-LSM the light is only emitted at the focus point. A pinhole is not needed for 
detection. Adapted from (Flügel et al., 2007). 
 
1.3.4 Passive transfer experimental autoimmune encephalomyelitis in the Lewis rat: The 
invasion steps of MPB-specific effector T cells from the periphery into the SC. 
By combining in vivo imaging with ex vivo quantification and functional characterization the 
fate of the transferred TMBP-GFP cells was followed during all the disease phases (Flügel et al., 






Just after transfer and independently from the state of the BBB the injected TMBP-GFP cells do 
not enter directly the CNS but they undergo a complex migratory tour through the periphery. 
Few minutes after injection effector T cells disappear from the blood circulation and enter the 
lung. From here T cells move to the bronchus-associated lymphoid tissue (BALT) and to the 
lung-draining mediastinal lymph nodes. Afterwards they re-enter the blood circulation and 
travel to the spleen (72-84 h after transfer) before they invade the SC (approximately 3 days 
after transfer) shortly before the onset of clinical symptoms. Already in the lung, TMBP-GFP 
cells drastically change their gene-expression profile: they down-regulate their activation and 
proliferation program and up-regulate locomotion and cell adhesion molecules. Moreover, 
they acquire the capacity to respond to inflammatory chemokines like CXCL9, 10 and 11. 
This acquired migratory phenotype allows them to overcome the BBB (Flügel et al., 2001; 
Odoardi et al., 2012).  
 
Clinical phase 
2P-LSM allowed visualizing the step of invasion of effector T cells in the target organ, the 
CNS (Bartholomäus et al., 2009). Due to the fact that inflammation in EAE mainly affects the 
SC most studies examine this part of the CNS and not the brain. It is extensively described 
that in order to get to the site of inflammation successive interactions of specific adhesion 
and/or signalling molecules on leukocytes and blood vessel endothelial cells are essential.  
First of all interactions between selectins (on endothelial cells) and their ligands (on 
leukocytes) allow leukocytes to adhere to the inflamed endothelium despite the blood flow. 
Moreover, integrins (like very late antigen-4, VLA-4 also known as α4β1) might be involved 
in this process. As a consequence of these interactions leukocytes start to roll on the vessel 
endothelium. Leukocyte arrest during rolling is rapidly triggered by chemokines, which 
activate integrins (VLA-4 or lymphocyte function-associated antigen-1 (LFA-1, also called 
αLβ2-integrin)) on the surface of leukocytes and thereby mediate their binding to their 
ligands, such as intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1), expressed by endothelial cells (Ley et al., 2007). Considered these 
well-described extravasation steps, it was surprising for Bartholomäus and colleagues to 
observe that the majority of effector TMBP-GFP cells (around 80 %) in the leptomeningeal 
vessels of the SC were not rolling but crawling on the intraluminal surface and this mainly 
against the blood flow (Bartholomäus et al., 2009). The crawling was specific of the SC 




of VLA-4 via monoclonal antibody treatment abolished both crawling and the transmigration 
of TMBP-GFP cells. The integrin LFA-1 was less important for the crawling process. 
Interestingly, also CNS-ignorant effector T cells reactive against ovalbumin (TOVA-GFP cells) 
crawled on the leptomeningeal surface. However, in contrast to TMBP-GFP cells the crawling 
duration of TOVA-GFP cells (i.e. the time these cells spent in crawling) was shorter (12 min 
against 15 minutes) and the percentage of crawling cells was lower (50 %). Moreover, very 
few TOVA-GFP cells were able to enter the SC (Bartholomäus et al., 2009). 
After diapedesis, TMBP-GFP cells transmigrated into the leptomeningeal area (fig. 1.4) where 
they started to monitor the abluminal vascular surface and, thereafter, the leptomeningeal 
space (fig. 1.4). Here, encephalitogenic T cells formed first short-lasting and later, with 
increase of inflammation, more long-lasting contacts with perivascular and meningeal 
phagocytes (fig. 1.4), which potentially can present their specific antigen. After the 
recognition of the antigen, the T cells became re-activated. Consequently, they up-regulated 
pro-inflammatory cytokines (IFN-γ, IL-17, TNF-α, IL-2) and surface activation markers 
(OX40, IL-2R) (Bartholomäus et al., 2009). In this re-activated state TMBP-GFP cells were able 
to induce further inflammation and penetrated deep into the SC parenchyma, first entering the 
white matter and then the grey matter, reaching a more or less equal distribution within these 







Figure 1.4 Illustration of the different invasion steps of MPB-specific effector T cells into the SC 
parenchyma. At Level I TMBP-GFP cells have reached the SC leptomeningel vessels. Here the TMBP-GFP cells scan 
the vessel surface and crawl intraluminally. After diapendesis into the leptomeningeal area TMBP-GFP cells start to 
scan the perivascular surface at Level II. Later TMBP-GFP cells detach from the abluminal vessel wall and start to 
scan the leptomeningeal area at Level III. During this process they get into contact with local antigen-presenting 
cells, which re-activate the TMBP-GFP cells and promote the invasion deeper into the SC tissue. Adapted from 
(Bartholomäus et al., 2009). 
 
1.3.5 T cell activation and the calcium-calcineurin-NFAT pathway  
The activation of CD4
+
 CNS antigen-specific T cells in the meningeal environment is 
essential for the invasion into the CNS parenchyma during the inflammatory processes 
(Flügel et al., 1999; Kawakami et al., 2004; Bartholomäus et al., 2009). Activation of a 
matured CD4 T cell occurs when APCs display the cognate antigen on their MHC class II 
molecules to the T cell (Goverman, 2009; Call, 2011). The T cell recognizes the presented 
antigen with its appropriate T cell receptor (TCR). Besides the described molecules, a set of 
co-stimulatory molecules and adhesion molecules are necessary for the full activation of a T 
cell (reviewed in Grakoui et al., 1999; Sharpe and Freeman, 2002; Huppa and Davis, 2003). 
After the binding and interaction of T cell receptor with the cognate antigen and appropriate 
ligands on APCs, the propagation of the T cell activation signal is carried out by specific 
intracellular signalling cascades. One important intracellular T cell activation cascade is the 
calcium-calcineurin-NFAT (nuclear factor of T cell activation) pathway (fig. 1.5). Briefly, 
after the binding of the cognate Ag presented on an MHC molecule to the TCR, an 
intracellular signalling pathway is initiated (for more details see fig. 1.5) which leads to the 
activation of the phosphatase calcineurin, the main modulator of NFAT. Once activated, 
calcineurin binds to the regulatory domain of NFAT and dephosphorylates its serine residues 
(Macian, 2005). The dephosphorylated NFAT is able to translocate into the cell nucleus and 
to induce gene transcription by binding to specific DNA regulatory regions of NFAT target 
genes via a DNA binding motif within its REL-homology domain (Macian, 2005). NFAT and 
its transcription-factor partners, which are also activated by TCR or co-stimulator binding, 
interact with one another mediating specific gene expression and thereby typical functional 
changes in activated T cells, like the expression of cytokines. The translocation of NFAT into 
the nucleus is an early event of T cell activation. The nuclear activity of NFAT is terminated 
by re-phosphorylation of the protein by export kinases leading to the nuclear export of NFAT 







Figure 1.5 The calcium-calcineurin-NFAT pathway. Ligation of the TCR triggers the activation of the NFAT 
pathway. First the receptor-associated tyrosine kinase activates PLC-γ. This enzyme catalyses the synthesis of 
IP3. IP3 binds to its receptor at iCa
2+
 stores and causes the depletion of Ca
2+
. Further elevation of the 
intracellular Ca
2+
 level is mediated by the opening of ICRAC in the plasma membrane. The increase of 
intracellular Ca
2+
 leads to the activation of calcineurin, which dephosphorylates the NFAT protein and thereby 









ion; ICRAC, Ion channel calcium-release-activated calcium ion channel; 
IP3, inositol-1,4,5-triphosphate; NFAT, nuclear factor of T cell activation; PLC-γ, phospholipase C-γ; TCR, T 
cell receptor. Modified from (Cope, 2002).
 
 
1.3.6 Disease course of ptEAE in Lewis rats 
Compared to MS EAE is less heterogeneous in its clinical presentation. The previously 
described classical Lewis rat EAE (chapter 1.3.2 and following chapters) induced by passive 
transfer of TMBP-GFP cells starts with an asymptomatic phase. After this symptom-free 
preclinical phase animals develop a rapid progressing monophasic flaccid paralysis starting 
around 3 days after transfer of encephalitogenic T cells (fig. 1.6). The first clinical sign of 
disease is the loss of body weight. Afterwards animals develop a flaccid tail and gait 
disturbances caused by beginning weakness of the hind limbs. At the peak of the disease, 4-5 
days after T cells transfer, the animals show a complete hind limb paralysis and bladder 







Figure 1.6 The monophasic disease course of ptEAE in Lewis rats. Shown are the different phases of EAE. 
The disease is starting with a prodromal or symptom-free preclinical phase. In the early clinical phase the animal 
is losing body weight and shows the first symptoms of disease. During the acute clinical phase the disease 
maximum is reached. The last phase is characterized by the recovery of the animals. Clinical score system: 0, no 
sign of disease; 1, tail paralysis; 2, gait disturbance; 3, hind limb paralysis; 4, tetraparesis and 5, moribund. 
Adapted from (Bartholomäus et al., 2009). 
 
 
The clinical presentation reflects indirectly the inflammatory area, in which TMBP cells have 
infiltrated. The paralysis in the rat ptEAE model is mainly caused by injury from infiltrating 
immune cells into the SC (Pender et al., 1995). 
 
1.3.7 Myelin basic protein: the classical antigen of EAE 
In the described rat ptEAE model (see above), T cells reactive against MBP are used to 
induce the disease. MBP is one of the major myelin proteins in the CNS. Evidence that MBP 
is important for the compaction of myelin comes from a naturally occurring shiverer mouse 
mutant, in which a large part of the MBP gene is deleted. As a consequence the shiverer 
mutant lacks most compact myelin in the CNS (Roach et al., 1985). Beside its importance for 
the adhesion of the cytosolic surface of multilayered compact myelin, MBP is described to 
interact with actin, tubulin, Ca
2+
-calmodulin, and clathrin, as well as negatively charged lipids 
(Boggs, 2006). The latter allows MBP to bind to the cytosolic surface of the oligodendrocyte 
membrane (fig. 1.7). In the rat the pathogenic role of T cells reactive against MBP is well 
established. In human multiple sclerosis, demyelination of neuronal fibres may occur as a 




the definition of a single protein, which is the target of the immune response is still elusive 




Figure 1.7 Myelinated neuron of the central nervous system and its proteins. The neuronal axons (blue) of 
the central nervous system are isolated by myelin sheaths formed by oligodendrocytes (yellow). The 
magnification shows the plasma membrane of oligodendrocytes wrapped around the axon and the localization of 
myelin proteins within the lipid bilayer. Some myelin and neuronal proteins are potential antigens of the 
autoimmune attack in CNS diseases like MS. Proteins, exogenously introduced into CNS structures by 
pathogens might also mediate autoimmunity. Myelin antigens like MBP are used to induce experimental 
autoimmune encephalomyelitis, the classical animal model for multiple sclerosis. MAG, myelin-associated 
glycoprotein; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; NA, antigen resident in 
neurons; OA, antigen resident in oligodendrocytes; P, proteins encoded by foreign DNA; PLP, proteolipid 
protein; Modified from (Hemmer et al., 2002). 
 
 
1.3.8 Limited diversity of EAE models 
Whereas the majority of MS patients develop inflammatory lesions in the supratentorial area, 
in rodent EAE models the lesions are generally localized in the SC (Pender et al., 1995). The 
factors determining the topography and the dynamics of inflammatory lesions in the different 
CNS compartments are still not clarified.  
Genetic factors could play a role considered that cortical demyelination can be modelled in 
certain rat strains by immunization with MOG protein without further treatment (Storch et al., 
2006). Cell-intrinsic properties have been implicated in the disease phenotype. It was shown 
that the ratio between TH1 and TH17 cells influences whether these cells infiltrate the brain or 




TH17 cells outnumber TH1 cells; if the immune response is driven by TH1 cells, classical SC 
infiltrates are observed (Stromnes et al., 2008). Moreover, it has been proposed that 
differential chemokine receptor or integrin expression might guide the effector T cells in 
different CNS compartments. TH17 but not TH1 cells were able to infiltrate the uninflamed 
choroid plexus via the CCR6-CCL20 axis in a mouse EAE model (Reboldi et al., 2009). 
Moreover, TH17 cells but not TH1 cells entered the supraspinal area in an LFA-1-dependent 
manner. Blockage of α4-integrin on TH17 cells prevented the α4-dependent entry into the SC 
favouring brain infiltration and thereby inducing an ataxic syndrome in mice (Rothhammer et 
al., 2011).  
Apart from effector T cell-intrinsic properties the differential lesion localization in the CNS 
compartments may also be due to different tissue responsiveness to certain cytokines. In 
mouse EAE it was suggested that IFN-γ receptor signalling of SC-resident cells is crucial for 
the induction of inflammation. In contrast, this signal inhibits cerebellar and brain stem 
inflammation (Wensky et al., 2005; Lees et al., 2008). Finally, other tissue-intrinsic properties 
like adhesion molecule expression, laminin composition of the basement membrane, local 
chemokine milieu or endothelia junction structure and function can play a role (Engelhardt 
and Sorokin, 2009). 
  
1.3.9 Cortical lesions in rodent EAE models  
Due to the fact that in the majority of rodent EAE models T cell infiltration mainly affects the 
SC, the possibilities to study the pathogenesis of cortical lesions are limited. In particular 
there is a lack of models mimicking cortical MS lesions. Supratentorial demyelination 
resembling the one observed in MS patients has been described in a marmoset model 
(Pomeroy et al., 2005; Merkler et al., 2006a). Due to the difficulties in animal husbandry this 
model cannot be widely used. Another model, which might reflect some features of cortical 
MS lesions, is the rat focal cortical EAE (Merkler et al., 2006b). Here, a stereotactic injection 
of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) and IFN-γ directly into 
the cortex of MOG pre-immunized Lewis rats evokes sub-pial and also some intracortical, 
vessel-associated demyelinating lesions associated with inflammatory infiltrates and 
complement deposition. (Merkler et al., 2006b).  
Cortical infiltration has also been induced in aEAE and ptEAE by using neuronal antigens 
like contactin-2/TAG-1 and -synuclein. Contactin-2/TAG-1 has emerged as a potential 
autoantigen recognized both by autoantibodies and TH1/TH17 cells by a proteomic approach 




populations and is localized at the juxtaparanodal region of myelinated axons. Transfer of 
TAG-1-specific T cells in Lewis rats induced very mild clinical symptoms mainly 
characterized by weight loss and transient loss of the tail tone. Histopathology studies showed 
mainly white matter and limited grey matter inflammation both in brain and SC largely 
restricted to the perivascular area (Derfuss et al., 2009).  
Cortical inflammation was also described after active immunisation with -synuclein peptides 
or passive transfer of T cells reactive against these peptides as detailed in the next paragraph. 
 
1.3.10 The β-synuclein protein - a potential antigen of MS 
The synuclein family comprises the three small, soluble proteins α-, β- and γ-synuclein 
(George, 2002). All synucleins are expressed in vertebrates, predominantly in neural tissue. 
The cellular functions of the synucleins are unknown. They might play a role in the regulation 
of membrane stability and turnover (Colley et al., 1997; Abeliovich et al., 2000; Murphy et 
al., 2000). The most well-known member of the synuclein family is α-synuclein. Under 
normal conditions α-synuclein is expressed in neurons whereas aggregated forms of the 
protein can also be found in somal inclusions of nigral dopaminergic neurons, called Lewy 
bodies, which are characteristic of sporadic and inherited forms of Parkinson`s disease 
(Mouradian, 2002). Interestingly, the α-synuclein level is elevated in the cerebrospinal fluid 
of MS and neuromyelitis optica patients. Therefore it might be an indicator for the extent of 
neuronal damage in these inflammatory demyelinating diseases (Wang et al., 2012).  
 
The β-synuclein protein is expressed predominantly in the CNS. It is the most conserved 
protein of the synuclein family. For example rodent β-synuclein is very similar to the one 
expressed in humans (it is to 97.8 % identical)(Lavedan, 1998). It is built up by 134 amino 
acids and highly expressed in the grey matter. In the human CNS the expression of β-
synuclein is starting during the development and maturation of the substantia nigra (Galvin et 
al., 2001). In the adult human CNS, β-synuclein expression expands to cortical regions as 
well as the thalamus, hippocampus, caudate nucleus and in the amygdala (Lavedan, 1998; 
Giasson et al., 2001). In cerebellum and SC the expression is more limited compared to 
cerebral tissue (Giasson et al., 2001). In rat and mouse nervous system it is expressed in the 
spinal cord, cerebellum and brain. More specifically, in rat brain it is expressed in the cortex, 
striatum, thalamus, olfactory bulb, hippocampus and less abundantly in the brain stem (Jakes 
et al., 1994; Iwai et al., 1995; Murphy et al., 2000; Giasson et al., 2001). Furthermore, the 




described dorsal root ganglion neurons, it is postulated that motor neurons lack the expression 
of β-synuclein, at least in humans and rodents (Giasson et al., 2001). A closer look at the CNS 
neuropil shows the predominantly synaptic distribution of β-synuclein, especially in the 
presynaptic nerve terminal, as a soluble protein (Maroteaux et al., 1988; Maroteaux and 
Scheller, 1991; Jakes et al., 1994; Iwai et al., 1995; Withers et al., 1997; Murphy et al., 2000). 
The physiological function of β-synuclein is unknown, but there are indications that it is 
involved in membrane-associated processes and might play a role in synaptic transmission 
(Jenco et al., 1998).There are indications from the rat animal models that the neuronal β-
synuclein might play a role in the autoimmune disease MS. Mor and Cohen selected peptides 
which were predicted to fit into the binding motive of the Lewis rat MHC class II I-A 
molecule RT1.B1. The chosen peptides were of various functions (for example surface 
receptors, structural or synaptic proteins) and, moreover, associated with neurodegeneration. 
By analysing the potential of these peptides to act as self-antigen and to induce CNS disease it 
was shown that only one of the 70 tested peptides was able to induce an EAE-like phenotype 
(Mor et al., 2003; Mor and Cohen, 2006). The immunisation with the non-myelin β-
synuclein93-111 peptide and passive transfer of β-synuclein93-111 peptide-activated T cells in 
Lewis rats induced the classical monophasic disease with moderate paresis of the hind limbs 
(Mor et al., 2003; Mor and Cohen, 2006). The mild EAE symptoms could be aggravated by 
pre-treatment with cyclophosphamide or radiation (Mor et al., 2003; Mor and Cohen, 2006). 
In a study of the Ben-Nun working group, the pre-treatment with cyclophosphamide or 
radiation was mandatory to induce EAE-like symptoms in Lewis rats (Kela-Madar et al., 
2009). Moreover, in all three studies β-synuclein peptide (including at least the amino acids 
92-110)-specific T cell clones were generated. The clones were pathogenic and caused mild 
clinical EAE symptoms (Mor et al., 2003; Kela-Madar et al., 2009). In the study of Mor in 
2003 perivascular and parenchymal mononuclear cell infiltrates were found in SC and the 
cerebral cortex (Mor et al., 2003). Other possible underlying pathomechanisms of β-
synuclein-induced EAE were not further analysed in these studies. Overall, these studies link 
neuronal antigens to EAE and give hints about a possible Ag, which might be involved in 








1.4 Aims of the project 
In this thesis my aim was to investigate the mechanisms responsible for the homing behaviour 
of effector T cells in the different CNS compartments. For this purpose GFP-transduced 
effector T cells reactive against myelin basic protein (TMBP-GFP) that are known to home 
preferentially in the SC were established in vitro and tested in vivo for their pathogenic 
potential by passive transfer in Lewis rats. The distribution of these cells in the periphery and 
in the different CNS compartments (brain and SC meninges, brain and SC parenchyma) was 
investigated by using histology and flow cytometry. The expression of cytokines and 
chemokine receptors that may be responsible for the different homing behaviour was 
evaluated by quantitative real-time PCR during the EAE course. In order to characterize the 
invasion pattern and the motility behaviour of these effector T cells in the target tissues two-
photon microscopy was performed on SC and brain meninges. The activation level of TMBP-
GFP cells in the CNS parenchyma was evaluated by using a genetically encoded NFAT 
biosensor. Finally, in order to investigate if antigen specificity can play a role in determining 
the distribution of the inflammatory lesions, fluorescently labelled effector T cells reactive 
against the neuronal antigen -synuclein (TβSyn-GFP) were established and compared in vitro 












2. Materials and Methods 
2.1 Materials 
2.1.1 Proteins 
Albumin from chicken egg white 
(OVA) 
Sigma Aldrich 
β-synuclein93-111 peptide (βSyn) 
from rat 
Peptide synthesis service, 
Biochemical Institute, Charité Berlin 
CCL5 (recombinant Cotton Rat) R&D Systems 
CCL19 (recombinant Mouse) R&D Systems 
CCL20 (recombinant Rat) R&D Systems 
CXCL11 (recombinant Murine) PeproTech 
CXCL12 (recombinant Rat) PeproTech 
Myelin basic protein (MBP) 






Mouse anti-rat CD4 Domain 1 
monoclonal antibody IgG1 
AbD Serotec 
Mouse anti-rat CD8α monoclonal 
antibody IgG1  
AbD Serotec 
Mouse anti-rat CD25 monoclonal 
antibody IgG1 (IL-2R alpha chain) 
AbD Serotec 
Mouse anti-rat CD134 monoclonal 





Mouse anti-rat TCR alpha/beta 
monoclonal antibody IgG1 
AbD Serotec 
 
Secondary Antibodies  
Goat anti-mouse IgG (H+L) antibody 
(allophycocyanin (APC) – conjugated)  
Jackson ImmunoResearch Laboratories  
 




- 0.15 mol/L NH4Cl  (Roth)  
- 1 mmol/L KHCO3 (Roth)  
- 0.1 mmol/L Na2×EDTA (Roth) 
- adjusted to pH 7.2 – 7.4 with HCl 
(Roth) 
Blocking buffer - 1x PBS (in-house production) 
- 5 % rat serum  (in-house production) 
Decalcification buffer - 14 % ethylenediaminetetraacetic acid 
tetrasodium salt hydrate (Sigma) 
- 86 % 1x PBS (in-house production)  
- adjusted to pH to 7,4 with glacial 
acetic acid (Roth) 
Eagles HEPES (EH) medium - 188.3 g/10L DMEM powder 
(Invitrogen) 
- HEPES 1M (Roth)  
Freezing medium day 2 - 80 % heat-inactivated horse serum 
(Biochrom AG) 
- 10 % TCM (in-house production) 
- 10 % DMSO (Roth) 





- 40 % TCM (in-house production) 
- 10 % DMSO (Roth) 
Isotonic Percoll - 9x Vol Percoll (GE Healthcare) 
- 1x Vol. 10x PBS  (in-house 
production) 
Lymohocyte seperation medium  
LSM 1077 
PAA 
Percoll Underlay - 7 mL Isotonic Percoll 
- 3.9 mL 1x PBS (in-house production) 
Perm/Wash Buffer BD Biosciences 
Phosphor buffered salt solution  
(PBS, 10x) 
- 8.10 mM Na2HPO4 (Roth) 
- 1.47 mM NaH2PO4 (Roth) 
- 137 mM NaCl (Roth) 
- 2.68 mM KCl (Roth) 
- adjusted to pH 7.2 
Re-stimulation medium (RM) - TCM (in-house production) 
- 1 % rat serum (in-house production)  
T cell growth medium (TCGM) - TCM (in-house production) 
- 10 % heat-inactivated horse serum 
(Biochrom AG) 
- 10 % conditioned medium from 
splenocytes treated with the mitogen 
Concanavalin A (ConA supernatant) 
(in-house production) 
T cell medium (TCM) - DMEM (Invitrogen) 
- 10 ml non-essential amino acids 
(Invitrogen) 





- 10 ml sodium pyruvate (Invitrogen)  
- 10 ml L-glutamine (PAN Biotech 
GmbH)  
- 10 ml L-asparagine monohydrate 
(Sigma Aldrich)  
- 4 μl 2-β-mercaptoethanol (13.6 
mol/L) (Invitrogen)                                    
- per litre 
Thawing medium - 90 % EH medium (in-house 
production) 
- 10 % heat-inactivated foetal bovine 
serum (Biochrom AG) 
 
2.1.4 Procedure Kits 
qPCR Master Mix Eurogentec 
RevertAid
TM





 Micro Kit Qiagen 
RNeasy
®
 Mini Kit Qiagen 
RNase-Free DNase Set Qiagen 
 
2.1.5 Chemicals / Sera / Solvents etc. 
Acetic acid (glacial) Roth 
Agarose Low Melt Roth 






Collagenase Sigma Aldrich 
Concanavalin A  Roth 







(3.000 MW, 70.000 MW) 
Invitrogen 
Diethyl ether  Roth 
Dimethyl sulfoxide (DMSO) Roth 
Distilled water DNase/RNase-free Invitrogen 
DMEM powder Invitrogen 
D(+)-Sucrose Roth 
Ethanol  Roth 




Horse serum Biochrom AG 
Hydrochloric acid (HCl) Roth 
Incomplete Freund’s Adjuvant Difco Laboratories 
Isoflurane Abbott 
Isotone sodium chloride solution 
(NaCl 0.9 %) 
Braun 




M. Tuberculosis H37Ra Difco Laboratories 
OptiPrep Axis-Shield 




 Lysis Reagent Qiagen 
Sodium chloride Gibco 
Thymidine, (methyl-3H) Hartmann Analytic 
Tissue Tek O.C.T Compound Sakura Finetek 
Trypan blue solution (0.4 %) Sigma Aldrich 
Trypsin EDTA (10-fold) PAA 
Xylariem Ecuphar 
2-propanol Roth 
4`,6-diamidino-2-phenylindole Sigma Aldrich 
 
2.1.6 Materials 
Base Molds (24 mm x 24 mm) Thermo Scientific 
Catheter Vasofix Safety Braun 
Cell strainer DB Falcon 
Cover Glasses (24 mm x 60 mm) Geyer 
FACS Tubes BD Falcon 
Flat Deck Thermo-Fast detection plates Thermo Scientific 









(5.0 μm Pore Size 
Polycarbonate Membrane) 
Microtome blades  Leica 
Nunclon
TM
Surface 96 well dish Nunc 
Perfusor FM BBraun 
Petri Dish (94 mm x 16 mm)  Greiner  
PP tubes sterile (15 ml / 50 ml) Greiner 
Prophyclean dental drill tip EVE 
Sieve (metal)  UMG Werkstatt 
SuperFrost Plus microscope slides Thermo Scientific 
Syringe needles 
(Sterican, different sizes) 
Braun 
Syringes (1 ml, 5 ml, 10 ml, 20 ml) Omnifix 
Tissue Culture Dish 
(60 mm x 15 mm, Cell+) 
Sarstedt 
Tissue Culture Dish 
(100 mm x 20 mm, Cell+) 
Sarstedt 
Tuberculin syringe BD Falcon 
 
2.1.7 Instruments and equipment 
Advanced single animal 
pressure-controlled ventilator 
Harvard Apparatus  
AxioCam HSM Carl Zeiss AG 
Axio Observer Carl Zeiss AG 




Balance CP124S Satorius 
BD FACS Aria BD Biosciences 
BD FACS Calibur BD Biosciences 
β-Counter Perkin Elmer 
Centrifuge 5415R Eppendorf 
Centrifuge 5810R Eppendorf 
Cryostat CM3050 S Leica Biosystems 
Heating pad Telemeter Electronic GmbH 
Heraeus Multifuge 1-SR Thermo Scientific 
Illuminator HXP 120 C Carl Zeiss AG 
Incubator Hera Cell 240 Thermo Scientific 
Isoflurane vaporizer Uno Roestvaststaal BV  
Laminar Flow Hera Safe Heraeus  
Laser Scanning Microscope 710 Carl Zeiss AG 
McIlwain Tissue Chopper Mickle Laboratory Engineering Company  
Neubauer counting chamber  Optic Labor 
OHMEDA 5250RGM GE Healthcare  
Perfusion pump Ismatec SA 
pH meter inoLab 
Shandon Cytospin 4 Thermo Electron Corporation 
StepOnePlus Real-Time PCR System Applied Biosystems 
Thermo-controller TC-1, elektronische Werkstatt, UMG  




10 W Ti: Sapphire chameleon laser Coherent Inc. 
 
2.1.8 Computer programs 
Animal Monitor software 7.3x Volker Staiger MPI of Neurobiology  
Axiovision 4  Carl Zeiss AG 
BD FACS Diva Software V 6.1.3 BD Bioscience 
CellQuest Pro BD Bioscience 
FlowJo V10 Tree Star, Inc. 
Graph Pad PRISM Graphpad Software, Inc. 
Office 2010 Microsoft 
Photoshop CS 5 Adobe Systems, Inc. 
Primer Express 3.0 Invitrogen 
StepOne
TM
 Software v2.0 Applied Biosystems 





2.2.1 Animals  
For all experiments Lewis rats on a LEW/Crl background (Rattus norvegicus) were used. The 
animals were bred and kept at the animal facility of the university medical centre Göttingen or 
obtained from Janvier (Le Genest St Isle, France). All experiments were approved by the 
appropriate committee in Braunschweig, Germany. 
2.2.2 Active EAE / Immunization 
Active EAE was induced by immunization of 8 to 10 week old female rats subcutaneously 
(into the base of the tail and into the hind limb popliteal cavity) with 150 μl guinea pig MBP 
protein (1 mg/ml) or β-synuclein93-111 peptide (βSyn) (amino acid sequence: 
LKPEEVAQEAAEEPLIEPL) (0.8 mg/ml) emulsified in an equal volume of complete 
Freund`s adjuvant containing Mycobacterium tuberculosis (2 mg/ml). The emulsion was 
prepared with the help of tuberculin glass syringes and a custom-made homogenizer. MBP 
was isolated from guinea pig brain as described in literature (Eylar et al., 1974). Briefly, 
guinea pig brain homogenates were freed of lipids via methanol/chloroform, followed by 
acidic extraction, neutralization, ammonium sulphate and acetone precipitation. Animals were 
sacrificed for primary T cell culture (see chapter 2.2.3.2.) or kept for the analysis of clinical 
disease progression. In the latter case the body weight of the animals was determined over the 
whole experimental period and animals were observed for disease symptoms and behavioural 
abnormalities. Clinical signs of classical EAE were assessed according to the following score 
system: 0, no sign of disease; 0.5, loss of tail tonus; 1, tail paralysis; 2, gait disturbance; 3, 
hind limb paralysis; 4, tetraparesis and 5, moribund. Animals were sacrificed when reaching a 
score of 4.5. Animals immunized with βSyn were moreover examined for uncommon disease 
signs like front limb weakness/paralysis, ataxia or hemiparesis.  
 
2.2.3 Primary T cell culture 
2.2.3.1 Culture of packaging cells  
GP+E86 packaging cells, producing a replication-deficient GFP or NFAT yellow fluorescent 
protein (YFP) retrovirus, were used to transduce T cells. The retroviral vector pMSCV used 




promotes the transfer of a resistance to the neomycin derivative G418 in combination with the 
GFP sequence (Odoardi et al., 2012). Moreover, the same vector was used to transfer a 
puromycin resistance together with the NFAT regulatory subunit and YFP sequence (Flügel et 
al., 1999; Lodygin et al., in press). 
Before co-culturing with primary T cells, packaging cells were cultured in selection medium 
(T cell medium (TCM) containing 10 % of foetal bovine serum (FBS) and G418 (0.4 mg/ml) 
or puromycin (2 μg/ml) depending on the resistance of the cells) in 10 ml cell culture dishes. 
The cells were kept under 5 % CO2 humidified atmosphere in an incubator at 37 °C.  During 
cell culture the adhesive packaging cells form monolayers. Upon reaching a confluence of 70-
80 % the packaging cell lines were splitted. For that purpose the cells were washed once with 
1x PBS and then incubated for 3-5 min with the endopeptidase trypsin (10x stock solution 
diluted 1:10 with PBS). After detachment of the cells from the cell dish the digestion process 
by trypsin was stopped by adding medium containing 10 % FBS. The desired amount of cells 
was taken and centrifuged to remove trypsin residues. After a centrifugation for 8 min with 
1200 rpm at 4 °C the supernatant was discarded and the pellet was resolved in TCM 
containing 10 % of FBS and 0.1 mg/ml G418 or 2 μg/ml puromycin according to cell line. 
Before co-culturing with primary T cells, the packaging cells were cultured for 2 days without 
any specific selection agent until a confluence of 70 % was reached. For cryo-conservation 
and thawing of packaging cells the same media and protocols as described for T cell culture 
were used (see below 2.2.3.2.). 
  
2.2.3.2 Primary rat T cell culture 
T cells retrovirally engineered to express fluorescent proteins and reactive against MBP or β-
synuclein peptide93-111 (TMBP or TβSyn) were generated as reported
 
(Flügel et al., 1999). The 
primary T cell culture work described here was performed under a laminar flow. The cells 
were kept under 10 % CO2 humidified atmosphere at 37 °C.   
 
For establishing antigen-specific CD4
+
 T cell lines, cells of the draining lymph nodes 
(popliteal, inguinal and paraaortal LNs) of immunized animals (see chapter 2.2.2.) were 
isolated in the preclinical phase of the disease at day 10 after immunization with MBP or at 
day 10-12 after immunization with βSyn. The isolated LNs were minced under and separated 
through a metal mesh. The cell suspension then was centrifuged (1200 rpm, 8 min, 4 °C) and 




lymphocytes were adjusted to 2 x 10
6
 per ml and co-cultured with 1.5 x 10
5
 per ml packaging 
cells. The cells were kept in a total volume of 100 µl re-stimulation medium (RM) in U-
bottom 96-well plates containing 10 µg/ml of MBP or 8µg/ml of βSyn. 
Two days after the start of the primary cell culture, T cell growth medium (TCGM) was 
added (50 μl per well). TCGM contains the supernatant of murine splenocytes stimulated with 
the mitogen Concanvalin A (ConA supernatant). ConA supernatant contains the growth factor 
IL-2 which induces the proliferation of T cells in culture. At day 3 or 4 of primary cell culture 
50 μl of medium per well were removed and cells were transferred into flat bottom 96-well 
plates. After the transfer 100 μl fresh TCGM containing G418 (0.4 mg/ml) or puromycin (1 
μg/ml) were added per well. Negative selection with G418 or puromycin was maintained for 
10 days. 
The first stimulation of T cells was performed 7 days after start of the culture. Firstly, 100 μl 
medium per well were removed and subsequently 1.4 x 10
6
 irradiated thymocytes in 100 μl 
RM were added per well in the presence of the βSyn peptide (8 µg/ml) or the MBP protein 
(10 µg/ml). The irradiation dose for the thymocytes (that were used as APCs) was 30 gray 
(Gy).  
Two days after re-stimulation 50 μl TCGM were added in each well to propagate T cell 
proliferation. Three to four days after re-stimulation the T cell wells with the best viral 
transduction rate (measured by GFP or YFP fluorescence intensity and the best growth 
capacity of the cells) were chosen and pooled into 60 mm dishes. 
  
2.2.3.3 Re-stimulation of T cells 
In the further propagation cycles T cells were re-stimulated in 60 mm dishes in a weekly 
rhythm. For this purpose 3.5 x 10
6
 resting T cells were co-cultured with 70 x 10
6
 irradiated 
thymocytes (30 Gy) per dish in RM containing the appropriate concentration of the antigen 
(10 μg/ml for MBP and 8 μg/ml for βSyn). At day 2 after re-stimulation TCGM was added to 
the T cell culture to promote further proliferation. To maintain optimal density T cells were 
transferred into 10 cm culture dishes and splitted further when necessary. MBP-specific T cell 
lines expressing GFP were called TMBP-GFP cells and βSyn-specific T cell clones expressing 
GFP were named TβSyn-GFP cells in short. MBP- or βSyn-specific T cells expressing NFAT and 






2.2.3.4 Cryo-conservation of T cells  
For cryo-conservation 10-30 x 10
6
 T cells were re-suspended in 1 ml freezing medium 2 or 6 
days after exposure to the cognate antigen and aliquoted in cryotubes. The tubes were 
transferred to precooled (4 °C) cryo-conservation freezing containers and subsequently frozen 
at -80 °C. For long-term storage T cells were transferred into liquid nitrogen. 
  
2.2.3.5 Thawing of cryo-conserved T cells 
In order to thaw cryo-conserved T cells, the cells were taken out of the liquid nitrogen and the 
freezing tubes were directly incubated in a 37 °C water bath. The cell suspension was then 
diluted 1:10 in thawing medium (containing 10 % FBS in EH) and washed once. The cells 
were then either immediately transferred in Lewis rat (when frozen on day 2) or cultured in 
TCGM medium for further propagation (when frozen on day 4-6). 
   
2.2.3.6 Characterization of established primary T cell lines 
Each established T cell line was characterized for phenotype and antigen specificity in vitro. 
Afterwards the pathogenicity of these lines was tested by transfer into Lewis rats (see chapter 
2.2.4). 
  
2.2.3.6.1 Characterization of T cell line phenotype by staining of surface markers 
TMBP-GFP and TβSyn-GFP cells were analysed for the expression of the cell surface markers TCR, 
CD4, CD8, and the activation markers OX40 and IL-2R on day 2 or on day 7 after stimulation 
with the cognate antigen. 
First, cells were transferred into 96- well plates with V shaped well bottom and subsequently 
the plates were centrifuged. Every centrifugation step in this chapter is performed at 4 °C for 
3 min with 1.200 rpm. The supernatant was discarded and the cell pellets were washed once 
with 1x PBS and once with 1x PBS containing 5 % rat serum (RS). The supernatant was then 
removed and the T cells were stained with mouse anti-rat CD4, CD8, IL-2R, OX40, TCR 
primary antibody (1 µg in 100 µl each) in 1x PBS containing 5 % RS. As a control for cross-
reactivity of the secondary antibody T cells in one well were incubated without the primary 
antibody. After an incubation of 30 min on ice, the cell pellets were washed twice. 
Afterwards, cell bound primary antibodies were detected with an APC-conjugated goat anti-




incubation time of 45 min on ice cells were washed once with 1 x PBS containing 5 % RS and 
once with 1x PBS. Subsequently, cells were pelleted by centrifugation and the supernatant 
was discarded. The T cell pellets were then re-suspended in 1x PBS and analysed using a BD 
FACS Calibur flow cytometer. The instrument is equipped with a 488 nm and a 635 nm laser 
for the detection of the GFP and the APC signal respectively. Data were analysed by using 
FlowJo V10 software. 
  
2.2.3.6.2 Characterisation of T cell line specificity via proliferation assay 
Each established T cell line was tested in vitro for antigen specificity by 
3
H-thymidine 
proliferation assay. First, MBP- or βSyn-specific T cells were re-stimulated in 96-well flat 
bottom plates. For this purpose, 5 x 10
4
 day 6 or day 7 T cells were seeded with 1 x 10
6
 
irradiated thymocytes (30 Gy) and 10 µg/ml or 8 µg/ml of the cognate antigen MBP or β-
synuclein, in 100 μl RM per well. As a positive control, T cells were incubated with 
thymocytes and 1.25 μg/ml of ConA. T cells incubated with thymocytes and the chicken egg 
protein ovalbumin (OVA) (10 µg/ml) or without any antigen were used as negative controls. 
All of these T cell-antigen combinations were plated at least in triplicates. T cells were 
incubated at 37 °C and 10 % CO2 humidified air in an incubator. 1.5-2 days after stimulation 
20 μl (37 MBq/ml) of radioactive methyl-
3
H-thymidine was added to each well. The cells 
were further incubated for 10-12 h before harvesting them on a filter membrane. The amount 
of radioactivity was then measured by a beta-counter and expressed as counts per minute 
(cpm). 
 
2.2.4 Passive transfer EAE 




encephalitogenic T cell blasts (day 2 after stimulation) in 1 ml of EH medium. The body 
weight of the animals was determined over the whole experimental period and animals were 
observed for disease symptoms and behavioural abnormalities. Clinical signs of classical EAE 
were measured by daily scoring of the animals as previously described (chapter 2.2.2). 
Animals were additionally examined for uncommon disease signs like front limb 
weakness/paralysis, ataxia or hemiparesis. Animals showing uncommon EAE signs were 





2.2.5 Animal preparation and organ processing 
Rats were sacrificed at time points of interest after induction of ptEAE by CO2 inhalation. The 
animal abdomen and chest were cut open from the ventral body side. Blood was collected 
directly from the heart of the animal with the help of a syringe prefilled with 300 μl 80 mM 
ethylenediaminetetraacetic acid (EDTA) and kept at RT until further processing. Afterwards, 
the lung and spleen were isolated. The animal was then inverted in order to access the dorsal 
side of the body. The skin above the vertebral column and the skull was removed. 
Subsequently, the vertebral column was dissected and cut open from the ventral side. The 
exposed spinal cord (SC) was removed from the column and cut into small pieces. With the 
help of fine forceps the meninges were stripped off and kept separately from the SC tissue. 
The skull of the animal was cut stepwise from the occipital bone in rostral direction until the 
frontal bone was reached. Afterwards, the skull was removed from the brain using strong 
forceps. Finally, the brain was detached from residual bone of the skull and the cerebellum 
was cut off. Both brain hemispheres were separated and the meninges were stripped from the 
brain parenchyma. All dissected organs were kept in EH medium on ice.  
In order to measure the number of infiltrated T cells in organs of interest, the different tissues 
were first weighed and then further processed as described below. 
 
Spleen. A single cell suspension was prepared by mashing the organ through a metal grid in 
EH medium. After centrifugation with 1200 rpm for 8 min at 4 °C the splenocytic cell pellet 
was dissolved and incubated for 3 min in 4 ml of ACK buffer on ice in order to lyse the 
erythrocytes. After dilution of the lysate with 45 ml of ice-cold 1x PBS the sample was 
pelleted by 8 min of centrifugation with 1200 rpm at 4 °C. The cell pellet was re-suspended in 
20 ml TCM and plated in 10 cm cell culture dishes to allow attachment of the macrophages to 
the dish bottom. Subsequently, the cells were incubated at 37 °C and 10 % CO2 humidified air 
in an incubator. After 1 h of incubation, the remaining non-adherent cells (including the T 
cells) were collected and centrifuged with 1200 rpm for 8 min at 4 °C. The cell pellet was re-
suspended in 5 ml of EH medium for further analysis. 
 
Blood. The EDTA-containing blood sample was diluted with an equal amount of 1x PBS (at 
RT). Afterwards, the blood mixture was gently stacked above a layer of 2 ml lymphocyte 
separation medium “LSM 1077” (RT) in a 50 ml falcon tube. In order to separate the 
lymphocytes from other blood components, the blood sample was centrifuged with 2000 rpm 




collected and transferred into a new falcon tube. After washing with 1x PBS, the cells were 
re-suspended in 1 ml EH medium.  
 
Lung. The lung was mashed extensively with a tissue chopper and subsequently incubated 
with 300 μl of 0.3 % collagenase and 150 μl of 1x PBS for 1 h at 37 °C under constant 
shaking. Subsequently, the lung tissue was forced through a metal grid and the cell suspension 
was collected in a falcon tube containing 10 ml EH medium. After centrifugation with 1200 
rpm for 8 min at 4 °C the cell pellet was re-suspended in 1 ml EH medium.  
 
CNS meninges and parenchyma. The parenchyma and meninges of the CNS were kept 
separately, mashed through a metal grid and suspended in 25 ml of cold EH medium. For 
gene expression analysis by quantitative real-time polymerase chain reaction (QRT-PCR) (see 
chapter 2.2.6) on total CNS tissue, a part of the cell suspension was separated, centrifuged and 
the pellet was re-suspended and stored in Qiazol reagent at -80 °C. The other part of the cell 
suspension was collected in a 50 ml falcon tube and mixed with 10 ml of Isotonic Percoll 
(Isopercoll). Afterwards, 10 ml of Underlay Percoll were gently pipetted under the cell 
suspension/Isopercoll layer and afterwards the tubes were centrifuged with 2780 rpm for 30 
min at RT with minimal acceleration/deceleration. The interphase of the sample was collected 
with a syringe and transferred to a fresh 50 ml falcon tube. The tube was filled up to 50 ml 
with 1x PBS in order to wash the cells and to dilute the remaining Percoll solution. After 
centrifugation for 8 min with 1200 rpm at 4 °C the supernatant was discarded and the 
lymphocyte-containing pellet was re-suspended in 1 ml EH medium for further analysis. 
If the lymphocytes from CNS parenchyma or meninges were destined to be further analysed 
in a cell migration assay, an OptiPrep
 
gradient instead of a Percoll gradient was used to 
extract the lymphocytes. The different CNS compartments were mashed through a metal grid 
as described before. In the case of the meninges, the obtained cell suspension (10 ml in EH 
medium) was mixed with 2.3 ml OptiPrep solution in a 15 ml falcon. The parenchymal cells 
however, were solved in 20 ml EH medium and the suspension was added to 4.6 ml OptiPrep 
in a 50 ml falcon tube. Both solutions were mixed shortly. Subsequently, meningeal and 
parenchymal cell suspensions were centrifuged with 750 rpm for 30 min at RT with minimal 
acceleration/deceleration. After centrifugation the supernatant was discarded and the pellet 
was washed and solved in 1x PBS. Afterwards, the cell suspension was centrifuged for 8 min 
with 1200 rpm at 4 °C and the remaining supernatant was discarded. The cell pellet was re-





After organ-dependent lymphocyte enrichment, the resulting cell suspensions were used for 
quantitative analysis of infiltrated TMBP-GFP or TβSyn-GFP cells. Alternatively, effector T cells 
were sorted by FACS for gene expression profile studies. 
 
For the quantitative analysis of infiltrated TMBP-GFP or TβSyn-GFP cells during EAE, a defined 
volume of the cell suspension of blood, lung, spleen and CNS was mixed with a defined 
number of BD Calibrite 3 APC beads. These cell-bead samples were analysed via BD FACS 
Calibur. The T cell number in every analysed sample was calculated by multiplying the 
number of detected cells with the ratio of supplemented beads to detected beads. To calculate 
the total number of TGFP cells in the entire cell suspension, the number of T cells in the 
analysed sample was multiplied with the ratio of the total suspension volume to sample 
volume. For further calculation of the number of GFP-positive T cells per organ, the 
calculated total number of T cells was normalized to the weight of the corresponding organ or 
to the blood volume.  
 
For ex vivo analysis of gene expression at single cell level, TMBP-GFP or TβSyn-GFP cells from 
different organs of EAE-affected animals were purified as described above. After the final 
centrifugation step the T cell pellet was re-suspended in 500 μl EH medium, containing 25 μl 
of 80 mM EDTA. The cell suspension was then filtered through a Cell Strainer mesh. 
Afterwards, GFP-positive T cells were sorted using a BD FACS Aria. After sorting, the GFP-
positive T cells were re-analysed for purity: only samples with ≥ 90 % purity were used for 
gene expression analysis. The sorted GFP-positive MBP- or βSyn-specific T cells were then 
pelleted by centrifugation (8 min, 1200 rpm, 4 °C) and re-suspended in 75 μl or 350 μl of β-
mercaptoethanol-RLT lysis buffer mixture, depending on the absolute number of sorted cells 
(see chapter 2.2.6.2. for further details). 
 
2.2.6 Quantitative real-time polymerase chain reaction (QRT-PCR) 
In order to analyse the expression level of specific genes of interest in total CNS tissue or in 
single T cells via QRT-PCR, the ribonucleic acid (RNA) was extracted from tissue samples 





2.2.6.1 Isolation of RNA using Quiazol
®
 Lysis Reagent 
Due to the sensitive nature of RNA the whole RNA extraction procedure was performed on 
ice. Homogenized tissue samples of brain meninges, SC meninges, brain or SC, were 
centrifuged and re-suspended in 1 ml Quiazol Reagent by repetitive pipetting, which induced 
cell lysis. Subsequently, the samples were stored at -80 °C or directly centrifuged at 12.000 x 
g for 10 min at 4 °C to remove the insoluble material from the homogenate. The pellet 
contained cell membrane debris and high molecular weight DNA. The supernatant, which 
contained the RNA, was transferred to a fresh tube. After this the samples were incubated for 
10 min at RT to allow the complete dissociation of nucleoprotein complexes. Subsequently, 
0.2 ml of chloroform were added and samples were mixed by hand for 15 sec and again 
incubated 10 min at RT. Afterwards, the samples were centrifuged at 4 °C and 12.000 x g for 
15 min. Following centrifugation the samples were separated into a lower phenol-chloroform 
phase, an interphase, and an upper aqueous phase which contained the RNA. After the 
transfer of the upper phase into a fresh tube, the RNA was precipitated by mixing the sample 
with 0.5 ml isopropanol and 1 μl glycogen. After an incubation time of 15 min at RT the 
samples were centrifuged at 4 °C for 10 min at 12000 x g. The RNA precipitate formed a gel-
like pellet on the bottom of the tube so that the supernatant could be easily removed. In order 
to dissolve the precipitated RNA, the pellet was washed once with 1 ml of 70 % ethanol. The 
sample was mixed by vortexing and centrifuged at 7.400 x g for 5 min at 4 °C. In a final step 
the RNA pellet was air-dryed for 5 min and dissolved in 11 μl of RNase-free water. The RNA 
was stored for shorter periods at -20 °C and for longer periods at -80 °C. 
  
2.2.6.2 Isolation of RNA using RNeasy
®
 Micro or RNeasy
®
 Mini Kit  





 Micro Kit following the manufacturer’s instructions. The RNeasy 
Micro Kit was used for 10 x 10 up to 5 x 10
5
 sorted cells and the RNeasy
®
 Mini Kit for more 
than 5 x 10
5
 sorted cells. As described above (see chapter 2.2.5), the sorted cells were pelleted 
and dissolved in 75 or 350 μl of β-mercaptoethanol RLT lysis buffer depending on cell count. 
The samples were stored at -80 °C or directly mixed by vortexing for 1 min at RT.  
Afterwards, 1 volume (75 or 350 μl) of 70 % ethanol was added and the solution was mixed 
by repetitive pipetting to homogenize the lysate. Subsequently, the samples were applied to an 
RNeasy micro or mini column placed in a collection tube and centrifuged at RT for 15 sec at 




The flow-through of the columns was discarded and 350 μl of RW1 Buffer were pipetted onto 
the columns. Following centrifugation at RT for 15 sec at 11000 x g the flow-through was 
again discarded. For the preparation of the DNase incubation mix, 10 μl DNase stock solution 
(RNase-Free DNase Set) were added to 70 μl of RDD Buffer (RNase-Free DNase Set) per 
sample and inverted gently by hand. In order to completely remove remaining DNA in the 
samples, 80 μl of DNase incubation mix were added to each sample column and incubated for 
15 min at RT. Afterwards, 350 μl RW1 buffer were added to the sample columns and 
centrifuged at RT and 11000 x g for 15 sec to wash the columns. After discarding the flow-
through the columns were put in fresh collection tubes, 500 μl RPE 1 Buffer were added to 
the columns and samples were centrifuged for 15 sec at 11000 x g at RT to wash the columns. 
The flow-through was discarded. Following the RNeasy
®
 Mini Kit protocol a second washing 
step with RPE 1 Buffer was performed (see first RPE 1 Buffer washing step). When using the 
RNeasy
®
 Micro Kit 500 μl of 80 % ethanol were pipetted onto the columns. Independent of 
the kit used, columns were centrifuged for 2 min at 11000 x g at RT, the flow-through was 
discarded and the columns were put into fresh collection tubes.  Following another round of 
centrifugation, to dry the silica-gel membrane, columns were again transferred to fresh 
collection tubes. Subsequently, 14 μl RNase-free water were pipetted directly onto the 
RNeasy silica-gel membrane to elute the RNA. Columns were centrifuged at RT and 11000 x 
g for 1 min. The elution step was repeated once with the flow-through from the first elution 
round to increase RNA yield. The RNA was frozen at 20 °C for short periods or -80 °C for 
longer periods of storage or directly used for cDNA synthesis. 
 
2.2.6.3 Reverse Transcription: cDNA synthesis using the RevertAid
TM
 First Strand 
cDNA Synthesis Kit  
The synthesis of cDNA from RNA was performed with the help of the Fermentas 
RevertAid
TM
 First Strand cDNA Synthesis Kit following the manufacturer’s instructions. For 
the cDNA synthesis random hexamer primers were used. These primers non-specifically bind 
to RNA templates and therefore can be used to synthesize cDNA from all possible RNA 
templates. First all required components of the Kit were thawed, mixed and centrifuged.  
Thereafter, 11 μl of sample RNA were pipetted into an RNase-free tube together with 1 μl of 
random hexamer primers, gently mixed and briefly centrifuged. The RNA-primer mix was 
then incubated at 65 °C for 5 min and subsequently chilled on ice for 1-2 min. This step 
denatures the RNA and allows the binding of the primers to the single strands. Afterwards, 




incubation the following components were combined: Per RNA sample 4 μl 5x Reaction 
Buffer, 1 μl RiboLock
TM
 RNase Inhibitor, 2 μl 10mM dNTP Mix and 1 μl RevertAid
TM
 M-
MuLV Reverse Transcriptase. This master mix was carefully mixed and 8 μl per sample were 
transferred to 0.5 ml RNase-free tubes. The RNA-primer mix was added to the 0.5 ml tubes 
containing the reverse transcriptase mix. The following cDNA synthesis reaction steps were 
performed using the Eppendorf Mastercycler EP Gradient. First, samples were incubated at 25 
°C for 5 min. Thereafter, cDNA synthesis was promoted by 60 min incubation at 42 °C. 
Finally, the cDNA synthesis was stopped by heat inactivation of the enzyme at 70 °C for 5 
min. The cDNA was stored ad -20 °C or directly used for quantitative real-time PCR. 
 
2.2.6.4 Relative quantification of cytokine and chemokine expression via quantitative 
real-time PCR 
Quantitative real-time PCR was used to determine the relative expression level of cytokines, 
cytokine receptors, chemokines or their receptors and adhesion molecules in total tissues or in 
single TMBP or TβSyn cells during the different EAE phases.  
The following rat-specific forward and reverse primers for IFN-γ, IL-17, CCL5, CCR5, 
CCR6, CCR7, CXCL9, CXCL10, CXCL11, CXCL12, CXCR3, CXCR4, LFA-1 VLA-4 and 
the house- keeping gene β-actin were designed for use with fluorescently tagged (fluorophore: 
Fam, quencher: Tamra) probes specific for each gene: 
 
β-actin primer sequences: 
 
Forward primer: 5’- GTA CAA CCT CCT TGC AGC TCC T -3’  
Reverse primer: 5’- TTG TCG ACG ACG AGC GC -3’  
Probe: 5’-Fam- CGC CAC CAG TTC GCC ATG GAT -Tamra-3’ 
 
CCL5 primer sequences: 
 
Forward primer: 5’- CCA CCT TGC AGT CGT CTT TGT C -3’  
Reverse primer: 5’- GAT GTA TTC TTG AAC CCA CTT CTT CTC -3’  
Probe: 5’-Fam- AGG AAC CGC CAA GTG TGT TGT GCC AAC -Tamra-3’ 
 
CCR5 primer sequences: 
 
Forward primer: 5’- GTT CTC CTG TGG ACC GGG TAT AG -3’  




Probe: 5’-Fam- AGC TTA CAC GAT CAG GAT TGA CTT GC -Tamra-3’  
 
CCR6 primer sequences: 
 
Forward primer: 5’- GGC CGG AAC ATT ATT GGA AA -3’   
Reverse primer: 5’- TTC CAG AGA CCG AGC CAT G -3’  
Probe: 5’-Fam- TGA ATT TCA CCG AGG CCA ACT ACG GA-Tamra-  
 
CCR7 primer sequences: 
 
Forward primer: 5’- GTG TAG TCC ACG GTG GTG TTC TC-3’  
Reverse primer: 5’- CTG GTC ATT TCC AGG TGT GCT -3’  
Probe: 5’-Fam- CCG ATG TAG TCG TCT GTG A -Tamra-3’  
 
CXCL9 primer sequences: 
 
Forward primer: 5’- TTG CCC CAA GCC CTA ACT G -3’  
Reverse primer: 5’- ACC CTT GCT GAA TCT GGG TCT AG -3’  
Probe: 5’-Fam- CAT CGC TAC ACT GAA GAA CGG AGA TC -Tamra-3’ 
 
CXCL10 primer sequences: 
 
Forward primer: 5’- CGT GCT GCT GAG TCT GAG T -3’  
Reverse primer: 5’- GTC TCA GCG GCT GTT CAT -3’  
Probe: 5’-Fam- CTC AAG GGA TCC CTC TCG CAA GAA C -Tamra-3’ 
 
CXCL11 primer sequences: 
 
Forward primer: 5’- GGT TCC AGG CTT CGT TAT GTT C -3’  
Reverse primer: 5’- ACC TTC CTT GAT TGC TGC CAT T -3’  
Probe: 5’-Fam- CTG TCT TTG CAT CGA CCG CGG AGT -Tamra-3’ 
 
CXCL12 primer sequences: 
 
Forward primer: 5’- GTC AAA CAT CTG AAA ATC CTC AAC AC -3’  
Reverse primer: 5’- GGT CAA TGC ACA CTT GTC TGT TGT -3’  





CXCR3 primer sequences: 
 
Forward primer: 5’- AGC AGC CAA GCC ATG TAC CTT -3’  
Reverse primer: 5’- TAG GGA GAT GTG CTG TTT TCC A -3’  
Probe: 5’-Fam- AGG TCA GTG AAC GTC AAG TGC TAG ATG -Tamra-3’ 
 
CXCR4 primer sequences: 
 
Forward primer: 5’- GGA GGT CAT CAA GCA AGG ATG T -3’  
Reverse primer: 5’- GGG TTC AGG CAA CAG TGG AA -3’  
Probe: 5’-Fam- TTC GAG AGC GTC GTG CAC AAG TGG -Tamra-3’ 
 
IFN-γ primer sequences: 
 
Forward primer: 5’- AAC AGT AAA GCA AAA AAG GAT GCA TT -3’  
Reverse primer: 5’- TTC ATT GAC AGC TTT GTG CTG G -3’  
Probe: 5’-Fam- CGC CAA GTT CGA GGT GAA CAA CCC -Tamra-3’ 
 
IL-17 primer sequences: 
 
Forward primer: 5’- GAG TCC CCG GAG AAT TCC AT -3’  
Reverse primer: 5’- GAG TAC CGC TGC CTT CAC TGT -3’  
Probe: 5’-Fam- ATG TGC CTG ATG CTG TT -Tamra-3’ 
 
LFA-1 primer sequences: 
 
Forward primer: 5’- CTG CTA CTC ATC CTA GCT GGA CTA CTC -3’  
Reverse primer: 5’- GCA GTT GCT GAC TTT GTA CTT GGT -3’  
Probe: 5’-Fam- TCC TGG GAT CTG CCC TGT CC - Tamra-3’  
 
VLA-4 primer sequences: 
 
Forward primer: 5’- GAA GGA AGA GTG TTC GTG TCA ATC A -3’  
Reverse primer: 5’- CGA CGA GCA CTC TTT TCC ATT -3’  





The primermixes for every primer pair were prepared for each gene of interest separately 
(table 1) and subsequently combined with a commercially available ready-to-use qPCR 
mastermix (qPCR Mastermix, Eurogentec) as illustrated in table 2.2.1. 
 
 
Table 2.2.1 Composition of primermixes 
CCL5/CCR 5/ 
CCR6/CXCL9/CXCL10/ 
CXCL11/ CXCL12/ CXCR3/ CXCR4/ 
IFN-γ / IL-2R / LFA-1/ VLA-4 
Concentration 
(mM) 
Fwd. primer 300 
Rev. primer 300 






Fwd. primer 300 
Rev. primer 900 




Fwd. primer 900 
Rev. primer 900 










Table 2.2.2 Reaction batch per well for QRT-PCR 
Reagent Volume 
qPCR mastermix 12.5 μl 
Primermix 5 μl 
cDNA template 
(1:20 diluted with Aqua dest.) 
7.5 μl 
Total volume 25 μl 
 
For QRT-PCR analysis, cDNA samples were combined with previously prepared master 
mixes in 96-well Flat Deck Thermo-Fast detection plates (see table 2.2.2).  
The expression of the housekeeping gene, cytokines and chemokines, chemokine receptors 
and adhesion molecules in the samples of interest were analysed in duplicates using the 
StepOne
TM
 Software v2.0 and the StepOnePlus Real-Time PCR System (Applied 
Biosystems).  
 
Table 2.2.3 QRT-PCR cycling conditions 
Temperature     Time     Number of cycles 
50°C      2 min     1x 
95°C      10 min     1x  
 
95°C       15 s           40 x 
60°C       1 min     
___________________________________________________________________________
   
The Delta-delta Ct method was used for quantification. β-actin was used as house-keeping 
gene. 
  
2.2.7 T cell chemotactic assay 
Directional migration of effector TMBP-GFP or TβSyn-GFP cells was analysed using a HTS 
Transwell-96 Well plate (5.0 μm Pore Size Polycarbonate Membrane). T cells were isolated 
ex vivo from blood of Lewis rat one day after T cell transfer (preclinical phase) or from the 
meninges and the parenchyma of the brain and SC at the peak of disease. T cell enrichment 
was performed as described before (see chapter 2.2.5). Afterwards, 75 μl of cell suspension in 




CXCL11 and CXCL12 (0.1 ng/ml) were diluted in 235 μl RM and added to the lower 
chamber. Every sample was tested for every chemokine in duplicate. For normalisation of 
chemokinetic T cell movement, duplicated wells containing RM without chemokines were 
used. In order to measure the T cell concentration in the original sample (input), a small 
portion of the cell suspension was kept on ice for final analysis. The transwell plate was 
incubated at 37 °C for 5 h under 10 % CO2 humidified atmosphere in the incubator. The 
number of effector T cells that had migrated through the membrane was counted by flow 
cytometry as described above (see chapter 2.2.5) and quantified as a percentage of the input. 
The migration index was calculated as the ratio of the percentage of input from non-treated to 
the percentage of input of chemokine-treated migrated T cells. 
 
2.2.8 Apoptosis detection assay   
In order to detect the percentage of apoptotic effector T cells in ex vivo samples, active 
Caspase-3 staining was performed according to the following protocol. 100 μl of CNS cell 
suspension (see chapter 2.2.5) were plated in 96-well V-bottom plates in duplicates. Cells 
were then fixed by incubating them in 100 μl of 2 % ice-cold PFA for 20 min on ice. After 
two steps of washing (one with 1x PBS and one with 1x BD Perm/Wash Buffer containing 5 
% RS) the cells were permeabilized for 30 min on ice in 1x BD Perm/Wash Buffer containing 
5 % of rat serum. Afterwards the samples were centrifuged and the pellet was re-suspended in 
100 μl of 1:500 diluted rabbit anti-rat active Caspase-3 primary antibody in 1x BD 
Perm/Wash Buffer containing 5 % of rat serum. 100 μl of rabbit IgG diluted 1:500 in 1x BD 
Perm/Wash Buffer containing 5 % of rat serum was used as negative control. Samples were 
then incubated for 45 min on ice, and then washed two times with 1x BD Perm/Wash Buffer 
containing 5 % of rat serum. For detection of the primary antibody, samples were incubated 
for 30 min on ice with a secondary APC-conjugated goat anti-rabbit IgG antibody (dilution of 
1:250 in 1x BD Perm/Wash Buffer containing 5 % of rat serum). Subsequently, the cells were 
washed two times with 1x BD Perm/Wash Buffer containing 5 % of RS and once with 1x 
PBS and then re-suspended in 1x PBS. The samples were acquired using BD FACS Calibur. 
Analysis of the percentage of active Caspase-3-positive T cells was performed by using the 
FlowJo V10 software. To ensure that the active Caspase-3 staining worked properly, 
apoptosis was induced in cultured TMBP-GFP or TβSyn-GFP cells by adding the protein synthesis 
inhibitor puromycin in a concentration of 1 μg/ml. T cells were incubated for 0 (control), 6, 
12 and 24 h at 37 °C and 10 % CO2 humidified air in an incubator. After incubation, the T 




to the protocol described above. 24 h after apoptosis induction 45-65 % of cultured T cells 
were detected as active-Caspase 3-positive (data not shown). Therefore the staining method 
was classified as a sensitive and specific way to label and detect apoptotic cells. 
 
2.2.9 Histology 
For the analysis of the invasion pattern of TMBP-GFP and TβSyn-GFP cells or TMBP-NAFT-YFP and 
TβSyn-NFAT-YFP cells into the CNS, animals were sacrificed at either onset or peak of the disease 
and perfused for histology. 
 
2.2.9.1 CNS tissue fixation and processing  
Animals were sacrificed by CO2 inhalation and afterwards fixed dorsally on a polystyrene 
plate for dissection. The abdomen was opened up with scissors and the peritoneum was cut to 
access the thorax of the animal without damaging inner organs. Subsequently, the thorax was 
opened to expose the heart. The apex of the left ventricle was cut and a hollow needle was 
inserted into the heart and clamped to prevent displacement during procedure. The right 
atrium was cut to intercept the blood circulation and the blood of the animal was washed out 
by a constant flow of filtered 1x PBS (4 °C) pumped into the left ventricle of the heart. 
Afterwards, the animal was fixed by perfusion with ice-cold 4 % paraformaldehyde (PFA). 
Then the animal was opened up from the dorsal side and the entire vertebral column was 
removed. Subsequently, the whole skull of the animal was removed from the skin and 
connective tissue and the lower jaw was cut off. The vertebral column and the skull were then 
incubated for 48 h in 4 % paraformaldehyde for post-fixation and afterwards transferred to 
decalcification solution containing the calcium chelator EDTA. The chelator binds calcium 
ions of the calcium phosphate within the bone and thereby softens its structure. The 
decalcification solution was renewed weekly. After 2-3 weeks of incubation at 4 °C, the bone 
was soft enough for cryo-sectioning. At this time point, the tissue was transferred to 30 % 
sucrose solution and stored at least for 72 h for dehydration. Thereafter, the tissue was 
embedded in Tissue TeK cryo matrix for cryo-sectioning. 
 
2.2.9.2 Cryo-sectioning 
Histological cryo-sectioning was performed with a Leica CM3050 S Cryostat with a chamber 




14 μm thick sections, whereas the decalcified skull was cut into 14 μm thick coronal sections. 
Brain and SC slices were immediately transferred to Superfrost glass slides and dried at 37 °C 
on a heating plate. After drying the sections were stored at -20 °C or directly used for staining 
or embedded for histological analysis. 
  
2.2.9.3 Staining of cell nuclei and embedding  
The brain and SC sections were re-hydrated with 1x PBS and afterwards post-fixed with 4 % 
PFA (4 °C) for 10 minutes. Afterwards the sections were washed with 1x PBS, embedded in 
FlouromountG and covered by coverslips. Cultured TMBP-NFAT-YFP or TβSyn-NFAT-YFP cells were 
spun onto glass slides with the help of a cytospin centrifuge. Brain and SC sections of TMBP-
NFAT-YFP or TβSyn-NFAT-YFP animals or the cultured cells themselves were stained with 4`,6-
diamidino-2-phenylindole (DAPI) after rehydration, post-fixation and washing of the material 
with 1x PBS, to visualize the nuclei of the cells. Firstly, sections were incubated for 10 min 
with 1 μg/ml DAPI in 1x PBS at RT. Afterwards, glass slides with the tissue sections or 
cultured cells were washed extensively with 1x PBS and covered as described before. 
 
2.2.10 Labelling of leptomeningeal APCs by intrathecal injection  
The intrathecal injection of Dextran Texas Red was performed in order to stain meningeal 
phagocytes in the leptomeningeal area of brain and SC. For each rat 0.7 μl of 3.000 MW 
Dextran Texas Red were dissolved in 20 μl NaCl and carefully drawn up into a tuberculin 
syringe (with a 27 gauge needle). The animals were anaesthetized by intraperitoneal (i.p.) 
injection of 1 μl/g body weight Ketamine/Xylariem solution (mixture 1:1.5). The animals 
were fixated in a stereotactical device and the syringe containing the dextran was placed into 
a stereotactical holder at 90 degree to the body surface. The injection of the dye was 
performed into the cisterna magna between the occipital bone and the atlas at a depth of 3.5 
mm. The dye was injected in two steps of 10 μl each with an interval of 1 min between single 
injections. Afterwards, the needle was left in its position for additional 5 min to ensure that 
the injected liquid was taken up by the liquor. Subsequently, the needle was gently removed 
and the animal was put into a separate cage until complete recovery. Moreover, during this 





2.2.11 Intravital live imaging with the two-photon laser scanning microscope  
Two-photon laser scanning microscopy (2P-LSM) was used for imaging TMBP-GFP or TβSyn-GFP 
motility patterns within CNS meningeal compartments in living animals. In order to access 
the dorsal spinal cord meninges the well-established “open spine window” procedure was 
performed as previously described (Bartholomäus et al., 2009). This preparation gives 
equivalent results to the “closed SC” preparation (Bartholomäus et al., 2009). To access the 
parietal cortex meninges however, thinned skull as well as open skull window preparations 
were established and compared. 
  
2.2.11.1 Animal preparation for intravital live imaging 
Animals were initially anaesthetised with a mixture of 1:1.5 Ketamine/Xylariem injected 
subcutaneously or intraperitoneally. Afterwards, animals were tracheally intubated and 
ventilated with 1.5-2 % isoflurane. If necessary an additional intramuscular injection of 1:1.5 
mixture of Ketamine/Xylariem was applied. The body temperature of the animal was 
measured with the help of a rectal probe and kept at a constant physiological level via a 
custom-made heating plate installed into the imaging stage. Electrocardiogram (ECG) was 
registered by epicutaneous electrodes during the entire imaging session. The animal was 
hydrated with saline via an intravenous catheter, which was additionally used for the injection 
of Dextran Texas Red to label the meningeal vessels during imaging. Depending on the site of 
investigation (spinal cord or brain) different surgical procedures were used to expose the 
tissue of interest. 
For imaging of the SC the dorsal fur was shaven and the underlying skin was disinfected with 
70 % ethanol. Subsequently, a midline skin incision of 2-3 cm above the end the thoracic and 
the beginning of lumbar vertebral column was performed. The paravertebral musculature was 
detached from the spine and the animal was stereotactically fixed onto the imaging stage. 
Afterwards, an agarose ring was applied above the vertebral body at the level where the 
laminectomy should be performed to keep the saline solution on top of the meningeal tissue 
during the imaging session. In order to get access to the SC, a vertebral window was 
generated by a laminectomy at the level Th12 / L1.  Afterwards the dura mater was carefully 
removed with fine forceps and the agar ring was filled with saline. Finally, the imaging stage 
was positioned under the 2P-LSM equipped with a 20x water immersion objective (numerical 




For imaging the brain meninges, the scalp of the animal was disinfected with 70 % ethanol. 
Afterwards, a midline scalp incision was performed extending from the neck region between 
the ears to the frontal portion of the head where the eyes are located. The animal was then 
stereotactically fixed onto a custom-made imaging stage. The connective tissue attached to 
the skull was carefully removed with a cotton bud. Subsequently, a high-speed micro-drill 
with a prophyclean dental drill tip was used to thin a circular area of the skull between the 
coronal, transverse and sagittal suture with medium drilling speed (see fig. 2.1). To avoid 
friction-induced heating of the skull and underlying tissues, short periods of drilling were 
followed by resting intervals. During these intervals saline solution was applied to 
additionally cool-down and clean the drilling surface. Moreover, during the thinning of the 
skull the applied pressure to the bone had to be minimised to avoid pushing the skull against 
the brain surface. However, due to the fact that a certain pressure is needed for successful 
thinning of the skull, it was helpful to keep the thinned region as small as possible. For 
imaging through the thinned skull window it is important that a uniform thickness of the skull 
is achieved. Irregular thickness may cause significant spherical aberration. The consequence 
is a reduced two-photon excitation and optical distortion of underlying structures (Helm et al., 
2009). After the flattening of the skull the imaging area was cleaned carefully with saline and 
an agarose ring was created to keep saline within the imaging area.  
 
For imaging through an open skull window, thinning of the skull was performed as described 
above. However, the outermost ring-like border of the thinned region was continuously 
thinned until the flattened skull area detached from the skull. Subsequently, the flattened bone 
fragment was carefully removed with fine forceps while keeping contact to the underlying 
dura mater at a minimum. Similar to the thinned skull preparation an agarose ring was created 
around the imaging field. Afterwards, the dura mater was covered with saline and the fixed 
animal was positioned under the 2P-LSM. Both the preparations could be performed in 







Figure 2.1 Skull preparation for intravital live imaging. The picture shows the areas at which the skull 
windows were established (between the coronal, transverse and sagittal sutures). For the thinned skull window, 
the skull was thinned and the imaging of the cortical meninges was performed through the bone. For the open 
skull window the bone was completely removed at the indicated area. The dura mater was left intact. To 
compare both skull windows the preparations were performed on the same animal at both sides of the sagittal 
suture. Adapted from (Paxinos and Watson, 2007). 
 
2.2.11.2 Two-photon laser scanning microscopy 
Two photon laser scanning microscopy was performed using a Zeiss Laser Scanning 
Microscope 710 combined with a Coherent 10 W Ti:Sapphire chameleon laser. Blood vessels 
were labelled by injection of 2000000 MW dextran tetramethylrhodamine. Meningeal 
phagocytes were labelled by intrathecal injection of 3000 MW Dextran Texas Red (see 
chapter 2.2.10). For the excitation of fluorophores a pulsed laser adjusted to a wavelength of 
880 nm was used. The emitted fluorescence was detected by non-descanned detectors 
equipped with 525 ± 50 and 630 ± 69 nm band-pass filters. In general, imaging of the parietal 
cortex (open skull window) and of the dorsal SC meninges was performed with 28 % or 22 % 
of the laser power, respectively. For imaging of deeper brain parenchyma or for the 
acquisition of 3D tile scans overview images, a laser intensity of 50-60 % or 40 % was used, 
respectively. For 3D time-lapse movies, scanning intervals of 32 sec and 58 cycles were used. 
 
After completion of the imaging session the animals were sacrificed. The brain and SC tissue 





2.2.11.3 Analysis of time-lapse videos, single Z-stacks and overview pictures generated 
by TPM 
Acquired 3D time-lapse videos were analysed with the help of the Imaris 7.1.1 software. In a 
first step, the automatic cell tracking function was used. Afterwards, the automatically 
generated T cell tracks were evaluated and corrected manually. The number of intraluminally 
rolling or crawling cells was counted manually. Subsequently, the percentage of rolling and 
crawling cells was calculated. The track properties of intraluminal and extravasated crawling 
T cells were exported to Microsoft Excel 2010 for further analysis. For the analysis of motile 
extravasated cells, tracks with a duration lower than 8 min and stationary cells were excluded. 
The generation of graphs and statistical tests was performed using Graphpad 5.0.4 software. 
Statistical analysis was performed using the two-tailed t-test (Mann-Whitney test) or one-way 
ANOVA (Kurskal-Wallis) test with confidence intervals of *P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.  
Single z-stacks or overview image files acquired with the TPM were exported as maximum 
intensity projections in TIF format by using the Zen 2009 software. The TIF files were loaded 
in Adobe Photoshop CS5 software and the images were corrected in tones and contrast for the 
different channels using the curve function. Moreover, three dimensional z-stacks or 
overviews of the imaging field were exported into Imaris 7.1.1 software to construct three-
dimensional pictures of the imaging area and to analyse imaging- or T cell-infiltration depth. 
 
2.2.12 Fluorescence Microscopy 
In order to visualize and subsequently analyse the invasion pattern of TMBP-GFP or TβSyn-GFP 
cells into the CNS, animals were sacrificed at onset and peak of EAE and prepared for 
histological analysis (see chapter 2.2.9). Overview pictures of brain and SC were acquired by 
a Zeiss Axio Observer Fluorescence Microscope equipped with a Zeiss Plan Apochromat 10x 
Air Objective (with a numerical aperture of 0.45). The light source was an HXP 120C metal 
halide lamp. Fluorescence emission was detected using a Zeiss AxioCam HSM. An excitation 
at 470 nm and emission at 509 nm was used for the detection of the green fluorescent TMBP-
GFP or TβSyn-GFP cells. For the red channel, excitation and emission were 558 nm and 583 nm, 
respectively. The exposure time was 600-700 ms for each channel. Overviews were acquired 
with the help of the Zeiss Axiovsion V 4.8 software and the MosaiX and focus correction 
function, which allow the automatic construction of an overview on the basis of single 




files, loaded into Adobe Photoshop CS5 software and corrected in tones and contrast for the 
different channels using the curves function. For the analysis of translocation events of DAPI-
stained TMBP-NFAT-YFP or TβSyn-NFAT-YFP cells at different time points during EAE in brain and 
SC sections, fluorescence emission was detected through a Zeiss Plan Apochromat 40x water 
emulsion objective (with a numerical aperture of 0.95). Fluorescence within the yellow 
spectrum was acquired with excitation at 514 nm, emission at 527 nm and an exposure time 
of 600-700 ms. The blue DAPI signal was acquired by 350 nm excitation and detected at 470 
nm with an exposure time of 10 ms. The analysed areas of brain and SC were acquired with 
the help of the Zeiss Axiovision V 4.8 software and the MosaiX and z-stack function. These 
functions allow scanning of the tissue pseudoconfocally in the z-axis. Single z-stacks were 
then “stitched” together automatically. Each plane of the acquired z-stack of a mosaic was 
then analysed for translocation events. T cells with nuclear or cytosolic NFAT reporter were 













3.1 Disease course of aEAE induced with the WM antigen MBP or the GM 
antigen βSyn. 
In order to compare the pathogenic potential of the myelin antigen myelin basic protein 
(MBP) and the neuronal antigen β-Synclein93-111 peptide (βSyn) in inducing EAE, Lewis rats 
were actively immunized. As expected, animals immunized with MBP showed the classical 
disease progression. The disease started at day 9 post immunization with loss of body weight 
(BWL) and flaccid paralysis of the tail tip. At the peak of the disease (day 12 after 
immunization) the animals’ hind limbs were paralysed and the front limbs were weak. Three 
days after the peak animals recovered from the symptoms (fig. 3.1 A). βSyn-induced aEAE 
started with a delay compared to MBP-induced aEAE at day 12 post immunization. The 
animals showed the same EAE symptoms as described for MBP-induced aEAE. However, the 
disease was in average less severe: even if a part of the animals exhibited complete hind limb 
paralysis and weakness of front limbs two days after disease onset, the most of them showed 
only tail paralysis. The animals had recovered completely three days after the peak of disease 





Figure 3.1 Clinical course of aEAE in MBP and βSyn immunized animals. Average body weight changes in 
per cent (line) and severity of clinical symptoms (bars) of Lewis rats after immunization with the MPB protein 
(A) or the βSyn peptide (B) emulsified in Complete Freund`s Adjuvant. The following score system was used: 0, 
no sign of disease; 0.5, loss of tail tonus; 1, tail paralysis; 2, gait disturbance; 3, hind limb paralysis; 4, 
tetraparesis and 5, moribund. p.i., post immunization. n = 6 per group. Representative data of 3 independent 
experiments are shown. 
 
3.2 Establishment and characterisation of TMBP-GFP and TβSyn-GFP cell lines  
EAE is a classical T cell-mediated disease that can be induced by either active immunization 
or by passive transfer of antigen-specific effector T cells. In order to investigate the specific 
role of T cells reactive against myelin or neuronal antigens in inducing EAE, T cells reactive 
against MBP or βSyn were established and tested in vitro for their phenotype and antigen 
specificity and in vivo for their pathogenic potential. Of note, the established T cell lines were 
retrovirally engineered to express GFP because the constant expression of the fluorescent 
marker allows the detection and quantification of these cells both in vitro and in vivo. For the 
phenotype characterisation TMBP-GFP and TβSyn-GFP cells were stained for the T cell specific 
surface markers CD4, CD8, TCR and the activation markers OX40 and IL-2R. Both lines 
showed a similar expression pattern of these markers (fig. 3.2 A and fig. 3.3 A). T cells of 
both specificities expressed the typical T cell marker TCR and were CD4-positive and CD8-
negative (representatively shown here for activated T cell blasts). Two days after re-
stimulation the activated T cell blasts show a high expression of the surface activation 
markers OX40 and IL-2R, which were down-regulated during the resting stage 7 days after 
re-stimulation (fig. 3.2 A and 3.3 A).  
The antigen specificity of each line was tested via 
3
H-thymidine proliferation assays. The 
TMBP-GFP and TβSyn-GFP cells were tested for their proliferative response to different antigens 
presented by APCs. TMBP-GFP and TβSyn-GFP cells proliferate specifically after the re-
stimulation with their cognate antigen MBP protein or βSyn peptide, respectively (fig. 3.2 B 
and 3.3 B). Moreover, the proliferative response of TMBP-GFP and TβSyn-GFP cells to their 
cognate antigen was similarly strong as the response to Concanavalin A (ConA), which acts 
as a non-specific stimulator of T cell proliferation (positive control). Both cell lines showed 
only limited response when cultured with a sham antigen, the chicken egg white protein OVA 
or without antigen (negative control) (fig 3.2 B and 3.3 B).  
Next the pathogenic potential of TMBP-GFP and TβSyn-GFP cells was tested in vivo. The disease 




subsequently scored on a daily basis according to the EAE scoring system described in fig. 
3.1. As expected, animals that received TMBP-GFP cells developed a classical monophasic 
paralytic disease. After a preclinical symptom-free phase, animals started to lose body weight 
and developed a flaccid tail 3 days post transfer (p.t.). At the peak of disease, approximately 5 
days p.t., the animals showed complete hind limb paralysis often in combination with 
weakness or paralysis of the front limbs (fig. 3.2 C and D). Afterwards the animals 
progressively recovered with complete remission of the symptoms 8 days p.t.. Also the 
animals that received TβSyn-GFP cells developed a monophasic paralytic disease with an 
incidence of 89 % (tab. 3.1). In total, 135 animals were analysed (tab. 3.1). Compared to the 
animals transferred with TMBP-GFP cells, these animals showed a prolonged preclinical phase 
(fig. 3.3 C). The onset of disease was between day 4 and day 5 after T cell transfer starting 
with identical symptoms as animals that were injected with TMBP-GFP cells (i.e. loss of body 
weight and paralysis of the tail). The peak of the disease was reached at day 7 post transfer. 
At this stage the animals showed the same paralytic symptoms as described before for the 
TMBP-GFP cell-induced ptEAE. Surprisingly, the animals recovered very rapidly reaching 
clinical score 0 from clinical EAE score 3-4 (complete hind limb paralysis, fig. 3.3 D left 
picture) in less than 24 h (fig. 3.3 C). Interestingly, four rats with βSyn-specific ptEAE 
showed uncommon disease symptoms. One animal suffered from hemiparesis, another animal 
showed a weakness of the right front limb (fig. 3.3 D middle picture) and two animals showed 
complete paralysis of both front limbs (fig. 3.3 D right picture).  
 






































Figure 3.2 Characterisation of TMBP-GFP cells in vitro and in vivo. (A) TMBP-GFP cell phenotype. Expression of T 
cell markers TCR, CD4, CD8 and activation markers OX40 and IL-2R on the surface of T cell blasts (2 days 
after re-stimulation) and resting T cells (7 days after re-stimulation) was measured by flow cytometry. IgG, 
isotype control. (B) TMBP-GFP cell antigen specificity assessed by 
3
H-thymidine proliferation assay. TMBP-GFP cells 
were co-cultured with irradiated thymocytes in presence of no antigen (control); Concanavalin A (ConA); β-
Synuclein93-111 peptide (βSyn); myelin basic protein (MBP); ovalbumin (OVA). 48 h later 
3
H-thymidine was 




depicted.  (C) Clinical course of ptEAE. The graph shows a representative disease course. Average body weight 
changes in per cent (line) and clinical symptoms (bars) following intravenous transfer of TMBP-GFP cells in Lewis 
rats. Average and SD are depicted. n = 8. (D) Photographic documentation of the typical ptEAE symptom hind 









Figure 3.3 Characterisation of TβSyn-GFP cells in vitro and in vivo. (A) TβSyn-GFP cell phenotype. Expression of T 
cell markers TCR, CD4, CD8 and activation markers OX40 and IL-2R on the surface of T cell blasts (2 days 
after re-stimulation) and resting T cells (7 days after re-stimulation) was measured by flow cytometry. IgG, 
isotype control. (B) TβSyn-GFP cell antigen specificity assessed by 
3
H-thymidine proliferation assay. The assay was 
performed as in fig. 3.2 B. Average and SD of triplicate samples are depicted. (C) Clinical course of ptEAE. The 
graph shows a representative disease course. Average body weight changes in per cent (line) and clinical 
symptoms (bars) following intravenous transfer of TβSyn-GFP cells in Lewis rats. Average and SD are depicted. n = 
6. (D) Photographic documentation of the typical ptEAE symptom hind limb paralysis at the peak of the disease 
(left), and the uncommon symptoms of front limb weakness (middle) or front limb paralysis (right picture). 
 
 
3.3. Infiltration kinetics of TMBP-GFP and TβSyn-GFP cells into the CNS 
After showing that antigen-specific effector TMBP-GFP and TβSyn-GFP cells both induce a similar 
monophasic paralytic disease, I next investigated the infiltration kinetics of these cells during 
the different ptEAE phases. In the preclinical phase, TβSyn-GFP cells showed a similar homing 
kinetic as TMBP-GFP cells. Cells of both specificities infiltrated first the lung and then 
drastically increased in blood and spleen just before entering the CNS (fig. 3.4, and published 
for MBP-specific T cells in (Flügel et al., 2001; Odoardi et al., 2012)). As described before, 
TβSyn-GFP cells induced a prolonged preclinical phase. During this phase a 2-40-fold higher 
number of infiltrated antigen-specific T cells could be detected in peripheral organs (fig. 3.4). 
At the end of the preclinical phase (day 3 post transfer for TMBP-GFP cells; day 4 post transfer 
for TβSyn-GFP cells) effector T cells started to enter the CNS. TMBP-GFP cells infiltrated the 
meninges of the brain and SC in similar numbers, whereas in the parenchyma MBP-specific T 
cells in the SC highly outnumbered those in the brain (fig. 3.5 A). TβSyn-GFP cell invasion into 
the meninges was more pronounced in the brain compared to the SC. Interestingly, the 






Figure 3.4 TMBP-GFP and TβSyn-GFP cell homing into peripheral organs during ptEAE. TMBP-GFP or TβSyn-GFP 
cell blasts were transferred into recipient rats and their infiltration into the peripheral organs lung, blood and 
spleen was determined during ptEAE by flow cytometry. (A) Infiltration kinetic of TMBP-GFP cells. (B) Infiltration 
kinetic TβSyn-GFP cells. Absolute numbers of TMBP-GFP or TβSyn-GFP cells /gram or ml of organ x 10
3







Figure 3.5 TMBP-GFP and TβSyn-GFP cell homing into the CNS during ptEAE. TMBP-GFP or TβSyn-GFP cell blasts 
were transferred into recipient rats and their infiltration into the brain meninges (Men Brain), SC meninges (Men 
SC), brain parenchyma (Brain) and SC parenchyma (SC) was determined during ptEAE by flow cytometry. (A) 
Infiltration kinetic of TMBP-GFP cells. (B) Infiltration kinetic TβSyn-GFP cells. Absolute numbers of TMBP-GFP or TβSyn-
GFP cells /gram of organ x 10
5
. #, number; g, gram. 
 
3.4 Infiltration route and tissue distribution of TMBP-GFP and TβSyn-GFP cells 
within the CNS 
3.4.1 Analysis at the onset of disease 
To validate the kinetic data of infiltrated TMBP-GFP and TβSyn-GFP cells and to learn about the 
entry route and the areas of the CNS that were targeted by these cells, decalcified cryo-
sections from the brain (coronal sections) and SC (transverse sections) of ptEAE-affected rats 
were prepared and histologically analysed by fluorescence microscopy. The advantage of 
decalcification is that this technique allows the sectioning of the CNS tissue with the 
surrounding bone. The meninges of the CNS remain intact and therefore meningeal 
infiltration by effector T cells can be analysed. At the onset of TMBP-GFP cell-induced ptEAE 
cortical meningeal and perivascular meningeal T cell infiltration was detected in brain coronal 
sections (fig. 3.6 A-C). Moreover, some TMBP-GFP cells infiltrated the sub-pial tissue and the 
ventricular ependyma at this time point (fig. 3.6. B and D). T cell infiltration in the choroid 
plexus epithelium was not observed in any of the analysed sections (fig. 3.6 D). In the 
meninges surrounding the hypothalamus first TMBP-GFP cell infiltrates were detected (fig. 3.6 
K). No inflammatory foci were visible in the parenchyma, both in the grey and white matter 
(fig. 3.6 A-E). A similar infiltration pattern of the brain, as described for TMBP-GFP cells, was 
observed for βSyn-induced ptEAE at this early time point of the disease (fig. 3.6 F-J, L).  
The analysis of SC transverse sections (thoracic level) from animals affected by TMBP-GFP cell 
-induced ptEAE showed the following typical homing pattern. At the onset of the disease 
TMBP-GFP cells started to infiltrate the tissue from the meninges. A characteristic meningeal 
ring of T cell infiltrates around the SC parenchyma was detected (fig. 3.7 A-B). In the vicinity 
of these cells first sub-pial and intraparenchymal TMBP-GFP cells were visible (fig. 3.7 B-C). In 
comparison, TβSyn-GFP cell infiltration in the SC meninges was less pronounced in the early 
EAE phase and mainly limited to the area where the meninges are attached to the dorsal horn 
and in close proximity to the grey matter (fig. 3.7 D-E). Surprisingly, intense deep grey matter 
βSyn T cell infiltrates around parenchymal vessels were observed (fig. 3.7 F). Moreover, at 




spinal cord (fig. 3.7 F). No infiltration foci in the white matter parenchyma could be observed 
(fig. 3.7 D-F). 
 
 
Figure 3.6 TMBP-GFP and TβSyn-GFP cell infiltration route into the brain at the onset of ptEAE. Representative 
fluorescence microscopic images of brain coronal sections (at the level of the hippocampus) at the onset of 
ptEAE induced either by TMBP-GFP cells (A-E and K) or by TβSyn-GFP cells (F-J and L). (A and F) Overview. 
Magnifications: (B/G) cortical meningeal and perivascular meningeal TGFP cell infiltrates, TGFP cell infiltration 
in: (C/H) parietal cortex/associated pia mater, (D/I) dorsal third ventricle with choroid plexus, (E/J) internal 
capsule, (K/L) hypothalamus. Closed arrows indicate TMBP-GFP or TβSyn-GFP cells, open arrows point to non-





Figure 3.7 TMBP-GFP and TβSyn-GFP cell infiltration route into the SC at the onset of ptEAE. Representative 
fluorescence microscopic images of SC transverse sections (thoracic level) at the onset of ptEAE induced either 
by TMBP-GFP cells (A-C) or by TβSyn-GFP cells (D-F). (A and D) Overview. Magnifications: TGFP cell infiltration 
in:  (B and E) pia mater and white matter, (C and F) deep grey matter. Closed arrows indicate TMBP-GFP or TβSyn-
GFP cells. (A and D) Scale bar: 200 μm, (B-C, E-F) magnifications (approx. 1.5 x). 
 
3.4.2 Analysis at the peak of disease 
As already indicated by the flow cytometric data (see chapter 3.3) only a low number of 
infiltrated effector T cells was seen by fluorescence microscopy in the brain parenchyma at 
the peak of ptEAE induced by TMBP-GFP cells. A limited fraction of pial and single sub-pial 
cortical TMBP-GFP cells were detected (fig. 3.8 B and C). Parenchymal T cell infiltration was 
visible adjacent to ventricular ependyma (fig. 3.8 D, here adjacent to the dorsal third 
ventricle) and in the hypothalamic tissue near to the hypothalamic meninges (fig. 3.8 K). The 
hot spots of parenchymal T cell infiltration however, were white matter regions like the 
internal capsule and the optic tract (fig. 3.8 E). In contrast, animals affected by TβSyn-GFP cell-
induced EAE show a high number of cortical grey matter infiltration at the peak of disease. 




Furthermore, parenchymal infiltration around the ventricular system and within the 
hypothalamus was observed (fig. 3.8 I and L). In general, myelin-poor regions were favoured 
by TβSyn-GFP cells whereas white matter-rich regions were mainly devoid of these cells (fig. 3.8 
J). In the SC, TMBP-GFP cells were spread not just throughout the white matter but also deeply 
inside the grey matter (fig. 3.9 A-C). In striking contrast to TMBP-GFP cell distribution, the 
massive infiltration of TβSyn-GFP cells was mostly confined to the grey matter parenchyma (fig. 
3.9 D-F).  
 
 
Figure 3.8 Regions of the brain infiltrated by TMBP-GFP and TβSyn-GFP cells at the peak of ptEAE. 
Representative fluorescence microscopic images of brain coronal sections (at the level of the hippocampus) at 
the peak of ptEAE. (A-E and K) Brain of a TMBP-GFP cell-induced ptEAE-affected animal. (F-J and L) Brain of 
a TβSyn-GFP cell-induced ptEAE-affected animal. (A/F) Overview. Magnifications:  (B/G) cortical meningeal and 
perivascular meningeal TGFP cell infiltration, TGFP cell infiltration in: (C/H) parietal cortex/associated pia mater, 




indicate TMBP-GFP or TβSyn-GFP cells, open arrows point to non-infiltrated choroid plexus epithelium. (A and F) 
Scale bar: 1000 μm, (B-E, G-L) magnifications (approx. 3 x). 
 
 
Figure 3.9 Regions of the spinal cord infiltrated by TMBP-GFP and TβSyn-GFP cells at the peak of ptEAE. 
Representative fluorescence microscopic images of SC transverse sections (thoracic level) at the peak of ptEAE. 
(A-C) SC of a TMBP-GFP cell-induced ptEAE-affected animal. (D-F) SC of a TβSyn-GFP cell-induced ptEAE-
affected animal. (A/D) Overview. Magnifications: TGFP cell infiltration in:  (B/E) pia mater and white matter, 
(C/F) deep grey matter. Closed arrows indicate TMBP-GFP or TβSyn-GFP cells (A and D) Scale bar: 200 μm, (B-C, 
E-F), magnifications (approx. 1.5 x). 
 
3.5 Apoptosis rate of TMBP-GFP and TβSyn-GFP cells in the CNS  
The previously described histological data indicated that the antigen specificity of effector T 
cells is important for entry site and distribution of these cells within the CNS. Next I asked 
whether differing apoptosis rate in TMBP-GFP and TβSyn-GFP cells in the target tissues could 
explain the observed different infiltration pattern. To answer this question, animals transferred 
either with TMBP-GFP or with TβSyn-GFP cells were sacrificed during the course of EAE. The 
CNS tissues were isolated and the percentage of effector T cells positive for active Caspase-3, 




This analysis revealed that independently from the EAE phase examined (onset, aggravation 
or peak) only a low percentage of TMBP-GFP cells extracted from brain and SC meninges and 
parenchyma were active Caspase-3-positive. The highest percentage of positive TMBP-GFP cells 
was detected in SC meninges whereas in brain meninges only half as much cells were 
apoptotic at the same time point. In the parenchyma no substantial differences in the 
percentage of apoptotic TMBP-GFP cells were detected (fig. 3.10 A). 
The levels of apoptotic TβSyn-GFP cells in the CNS of ptEAE-affected animals were also at a 
low level during disease progression. Similar to the observation made for TMBP-GFP cells, no 
substantial differences in the percentage of active Caspase-3-positive TβSyn-GFP cells were 







Figure 3.10 The apoptosis rate of TMBP-GFP and TβSyn-GFP cells in the CNS during EAE. TMBP-GFP or TβSyn-GFP 
cells were isolated from CNS tissue homogenates of ptEAE-affected animals during the course of the disease. 
TGFP cells from brain meninges (Men Brain), SC meninges (Men SC), brain parenchyma (Brain) and SC 
parenchyma (SC) were stained for active Caspase-3. The percentage of positive TGFP cells was determined via 
flow cytometry. (A and B) left side: Representative dot plots show active Caspase-3 expression of TMBP-GFP cells 
(A) or TβSyn-GFP cells (B) extracted from the indicated CNS compartments at the peak of the disease. (A and B) 
right side: Diagrams show the percentage of active Caspase-3-positive TMBP-GFP cells (A) or TβSyn-GFP cells (B) in 
different CNS compartments of ptEAE-affected animals at disease onset, during disease aggravation and at the 
peak of the disease. 
 
3.6 Pro-inflammatory chemokine expression in MBP- and βSyn-induced 
ptEAE 
Next it was investigated whether a differential expression of chemokines in the different CNS 
compartments could justify the observed homing pattern of effector T cells. Therefore, the 
expression of the chemokines CCL5, CXCL9, CXCL10, CXCL11 and CXCL12 was analysed 
via QRT PCR in the naïve situation or at the onset and peak of EAE induced by TMBP-GFP cells 
or TSyn-GFP cells. At the day of T cell transfer (day 0), only a very low expression of the 
inflammatory chemokines CCL5, CXCL9, CXCL10 and CXCL11 was observed in the 
meninges and parenchyma of the CNS in both ptEAE types (fig. 3.11). In contrast, a high 
basal expression of CXCL12 was detected in the CNS meninges of these animals (fig. 3.11 A 
and B, upper rows). During EAE a strong reduction of CXCL12 expression was seen in brain 
and SC meninges independent of the antigen specificity of the disease-inducing T cells (fig. 
3.11, upper rows).  
During EAE induced by TMBP-GFP cells the expression of the inflammatory chemokines 
CXCL10 and CXCL11 was markedly up-regulated in SC meninges and parenchyma, 
especially at the onset of the disease. In addition, the CXCL9 level was elevated during 
ptEAE in the SC parenchyma compared to base level. The meninges and parenchyma of the 
brain showed only mild up-regulation of the chemoattractive guiding cues during disease 
progression compared to SC tissues (fig. 3.11 A).  
In the meninges and SC parenchyma of animals affected by βSyn-induced ptEAE lower levels 
of inflammatory chemokines compared to animals affected by TMBP-GFP cell-induced ptEAE 
were observed. Taken together, these data indicated that the expression of the inflammatory 







Figure 3.11 Expression of pro-inflammatory chemokines in the CNS during TMBP-GFP and TβSyn-GFP cell-
induced ptEAE. Total CNS tissue homogenates were analysed for the expression of the pro-inflammatory 
chemokines CCL5, CXCL9, CXCL10, CXCL11 and the homeostatic chemokine CXCL12 by QRT-PCR.  (A) 
left column: TMBP-GFP cell-induced chemokine expression. (B) right column: TβSyn-GFP cell-induced chemokine 
expression. Day 0, day of transfer; Men Brain, brain meninges; Men SC, SC meninges; Brain, brain 
parenchyma; SC, SC parenchyma; onset, onset of ptEAE; peak, peak of ptEAE. Specific copies in relation to β-





3.7 Chemokine receptor and integrin expression profile of TMBP-GFP and 
TβSyn-GFP cells during ptEAE 
It has previously been shown that after transfer TMBP-GFP cells undergo in the peripheral 
organs a complex reprogramming that allow them to overcome the blood-brain barrier (BBB). 
More specifically the effector T cells down-regulate the activation markers and up-regulate 
the expression of several integrins and chemokine receptors (Odoardi et al., 2012). Therefore, 
I investigated whether the expression of chemokine receptors and integrins on the surface of 
effector TMBP-GFP and TβSyn-GFP cells is crucial for the observed divergent CNS homing pattern 
(see chapter 3.3 and 3.4). TGFP cells of both specificities were purified via fluorescence 
activated cell sorting (FACS) from the blood of the TGFP cell-injected animals at the onset of 
the disease and analysed for the expression of their surface receptor profile by QRT-PCR. 
TMBP-GFP and TβSyn-GFP cells expressed a similar pattern of the chemokine receptors CXCR4, 
CCR7, CCR6, CXCR3, CCR5 and of the integrins VLA-4 and LFA-1. The expression of 
CXCR3, CXCR4 and VLA-4 was more pronounced than the expression of the other surface 
receptors for both antigen-specific T cells (fig. 3.12 A). To flank the gene expression analysis 
with functional data a T cell migration assay was performed in which the chemotactic 
migration of the TMBP-GFP or TβSyn-GFP cell towards the chemokines CCL5, CCL19, CCL20, 
CXCL11 and CXCL12 was analysed. Both effector T cell types sorted from blood in the early 
phase of the disease showed a preferential migratory response to CCL20 and CXCL11 (fig. 
3.12 B). According to these data the chemokine receptor/integrin expression profile in the 
periphery was not responsible for the observed different infiltration pattern of TMBP-GFP and 
TβSyn-GFP cells in the target tissues. 
Next I investigated the chemokine receptor and integrin expression profile and the 
chemotactic behaviour of effector T cells of both specificities sorted from CNS tissue at the 
onset and peak of the disease. At both time points of investigation, auto-reactive TMBP-GFP and 
TβSyn-GFP cells show a similar expression pattern, as discovered previously for blood-purified 
effector T cells: Independently from the original CNS compartment, CXCR3 and CXCR4 
were the most expressed chemokine receptors and in the integrin group VLA-4 was more 
expressed than LFA-1 (fig. 3.13 A and B). In addition, the same migratory response pattern of 
effector T cells to the inflammatory and the homeostatic or lymphoid chemokines was 
detected at the peak of disease. CCL20 and CXCL11 seemed to be chemo-attractive for both 
effector T cell types (fig. 3.14 A and B). In summary, there was no difference in the 




matter-specific T cells. Therefore, it seems unlikely that these proteins are responsible for the 
differences in T cell homing behaviour between TMBP-GFP and TβSyn-GFP cells.  
 
Figure 3.12 Surface expression of chemokine receptors and integrins and chemotactic response of blood-
derived effector TMBP-GFP and TβSyn-GFP cells during ptEAE. EAE was induced by the transfer of TMBP-GFP or 
TβSyn-GFP cells to Lewis rats. Peripheral blood TGFP cells were collected and (A) purified by FACS sorting at the 
early disease onset or (B) enriched by an OptiPrep gradient at the same time point. (A) The expression of the 
chemokine receptors CXCR4, CCR7, CCR6, CXCR3, CCR5 and the integrins VLA-4 and LFA-1 was analysed 
by QRT-PCR. Specific copies in relation to β-actin copies are shown. Data of two independent experiments are 
shown. Average and SD are depicted. (B) The ability of effector T cells to migrate towards the chemokines 
CCL5, CCL19, CCL20, CXCL11 or CXCL12 was tested by a transwell migration assay. Migrated T cells were 
counted by flow cytometry and the migratory response of the T cells was calculated as cell migration index (ratio 
of transmigrated T cells in response to chemokines versus control without chemokines). One representative data 









Figure 3.13 The surface expression pattern of chemokine receptors and integrins of CNS-derived effector 
TMBP-GFP and TβSyn-GFP cells during ptEAE. EAE was induced by the transfer of TMBP-GFP or TβSyn-GFP cells to 
Lewis rats. TGFP cells in CNS tissue homogenate were enriched by a percoll gradient and further purified by 
FACS at disease onset (A) or at the peak of the disease (B). The expression of the chemokine receptors CXCR4, 
CCR7, CCR6, CXCR3, CCR5 and the integrins VLA-4 and LFA-1 was analysed by QRT-PCR. Specific copies 
in relation to β-actin copies are shown. Data of three independent experiments are shown. Average and SD are 
depicted. Men Brain, brain meninges; Men SC, SC meninges; Brain, brain parenchyma; SC, SC parenchyma. 
 
 
Figure 3.14 The migratory response pattern of CNS-isolated effector TMBP-GFP and TβSyn-GFP cells in TMBP-
GFP or TβSyn-GFP cell-induced ptEAE. EAE was induced by the transfer of TMBP-GFP or TβSyn-GFP cells to Lewis 
rats. Animals were sacrificed at the peak of the disease. TGFP cells in CNS tissue homogenate were enriched by 
an OptiPrep gradient. The ability of effector T cells to migrate towards the chemokines CCL5, CCL19, CCL20, 




cytometry and the migratory response was calculated as cell migration index (ratio of transmigrated T cells in 
response to chemokines versus control without chemokines). One representative data set of two independent 
experiments is shown. Men Brain, brain meninges; Men SC, SC meninges; Brain, brain parenchyma; SC, SC 
parenchyma. 
 
3.8 The activation state of effector T cells in the target organ and its role for 
CNS homing. 
It was shown that effector T cells, which overcome the BBB, have to be locally re-activated 
by APCs presenting their cognate antigen in order to penetrate deeper into the CNS. This re-
activation is strongly dependent on the availability of the antigen and the specificity of T 
cells. Therefore, only T cells, which encounter their specific antigen become activated and the 
activation state of effector T cells is crucial for the CNS homing behaviour (Bartholomäus et 
al., 2009). In order to test if the CNS activation profile is consistent with the infiltration 
pattern of TMBP-GFP or TβSyn-GFP cells, the CNS tissue of ptEAE-affected animals (MBP- and 
βSyn-specific subtypes) was analysed at the onset and the peak of the disease for the 
expression of the key T cell activation markers IFN-γ and IL-17 by QRT-PCR. At the onset of 
the disease a higher expression of both activation markers was detected in the SC meninges 
and even more pronounced in SC parenchyma compared with brain meninges and 
parenchyma during TMBP-GFP cell-induced ptEAE (fig. 3.15 A). The same tendency was seen 
at the peak of the disease in the parenchyma (fig. 3.15 C).  
A different activation profile was observed in the target tissues of TβSyn cells:  Here, the 
expression level of the activation markers in the meninges of brain and SC were similar at 
disease onset, whereas in the parenchyma there was a higher expression of IFN-γ and IL-17 in 
SC compared to brain (fig. 3.15 B). At the peak of the disease, the expression of both 
activation markers was on a similar level in all analysed tissues (fig. 3.15 D).  
To learn about the expression of key activation markers of effector T cells on their way to the 
CNS at the T cellular level, TMBP-GFP and TβSyn-GFP cells were sorted from blood of the 
respective ptEAE-affected animals in the early onset of the disease and analysed via QRT-
PCR. Both cell types express IFN-γ and IL-17 at a similar level and in a similar IFN-γ to IL-







Figure 3.15 Expression of activation markers in CNS tissue. EAE was induced by the transfer of TMBP-GFP or 
TβSyn-GFP cells to Lewis rats. CNS tissue homogenate was analysed at disease onset (A-B) or at the peak of the 
disease (C-D) for the expression of the key cytokines IFN-γ and IL-17 via QRT-PCR. Of three independent 
experiments one representative data set is shown. Bars show specific copies in relation to β-actin copies. 
Average and SD of duplicate measurements are shown. Men Brain, brain meninges; Men SC, SC meninges; 








Figure 3.16 Expression of activation markers by effector T cells during ptEAE. EAE was induced by the 
transfer of TMBP-GFP or TβSyn-GFP cells to Lewis rats. TGFP cells from blood or CNS tissue homogenate were 




onset (A-D) or at the peak of the disease (E-F). The expression of the key cytokines IFN-γ and IL-17 was 
analysed by QRT-PCR. Of three independent experiments one representative data set is shown. Bars show 
specific copies in relation to β-actin copies. Average and SD of duplicate measurements are shown. Men Brain, 
brain meninges; Men SC, SC meninges; Brain, brain parenchyma; SC, SC parenchyma. 
 
In order to evaluate the previous results from total CNS tissue at effector T cell level, 
cytokine expression analysis was additionally performed with sorted TMBP-GFP and TβSyn -GFP 
cells derived from total CNS tissue homogenates. This analysis revealed that independently 
from the antigen specificity, the time point or the tissue analysed the effector T cells sorted 
from the CNS were always more activated than the ones sorted from blood (fig. 3.16 A- F), 
which indicates that an activation of these T cells in the target tissue occurred.   
TMBP-GFP cells sorted from meninges and parenchyma of the SC showed a higher activation 
marker expression compared to those isolated from brain meninges and parenchyma at the 
onset of the disease (fig. 3.16 C) whereas this tendency was less pronounced at the peak of the 
disease (fig. 3.16 E). Consistently with the analyses of total CNS homogenates (fig. 3.15 B 
and D, upper graphs), TβSyn-GFP cells sorted from the meninges of brain and SC show a nearly 
equal level of marker expression at the onset and the peak of disease (fig. 3.16 D and F, upper 
graphs). A similar expression pattern as in the meninges was detected in the parenchyma of 
the brain and the spinal cord (fig. 3.16 D and F). In general it was conspicuous that the 
activation marker expression was higher at disease onset compared to the peak of disease 
independent of the tissue analysed (fig. 3.15 and 3.16). 
 
3.9 Visualization and in situ analysis of effector T cells in the target organ 
3.9.1 Establishment of imaging windows to access CNS meninges 
So far, all the described results were based on ex vivo analysis. In order to visualize TMBP-GFP 
or TβSyn-GFP cells directly in the target organ in living animals and to investigate their function 
at single cell level, live imaging by two-photon laser scanning microscopy (2P-LSM) of 
meninges of brain and spinal cord was performed. To access the dorsal spinal cord meninges, 
the “open spine window” preparation was performed, which is a well-established method in 
our lab. However, in order to access the meninges of the parietal cortex, an appropriate 
preparation method had to be established. Two different methods, a closed thinned skull and 
an open skull window, were developed, compared and tested for their applicability.  
When compared, a higher laser power had to be applied through the thinned skull window in 




depth of the open skull window was greater (200 µm vs. 100 µm) and it allowed the detection 
of deeper infiltrated T cells in the leptomeningeal area of the descending perforant vessels and 
of the parenchymal capillaries (tab. 3.2 and fig. 3.17 A-B). Moreover, it has previously been 
shown that the use of an open skull window for in vivo imaging was associated with high 
dendritic spine turnover and substantial glia activation starting 2 days after surgery (Xu et al., 
2007). In our study the imaging session never lasted more than 12 hours, a time point not 
analysed in the mentioned work. However, considered these caveats, a parallel analysis of the 
motility behaviour of effector T cells was performed through both cranial windows at 
different time points of the disease. No differences in the motility pattern of extravasated 
effector T cells in the leptomeninges were observed. Imaged TMBP-GFP cells showed the same 
speed and straightness when imaged through one or the other cranial window (fig. 3.17 C). 
Therefore, the open skull window, which provides a deeper imaging field and thereby enables 
the imaging of descending vessels and deeper T cell infiltrates, was chosen for further 
experiments (fig. 3.17 B).  
 
Table 3.2 Comparison between both established cranial window types for two-photon live 
imaging of effector T cell motility behaviour in brain leptomeninges 








No remarkable damage  
method applicable independent 
of inflammation level 
 
 
Limited leakage of dural 
blood vessels (at a high 
level of inflammation)  
 
Laser power 35 % 28 % 
Imaging depth Approx. 100 µm Approx. 200 µm 
 
Motility behaviour of 






No statistical differences to 
open skull window 
(see fig. 3.17 for further details) 
 
 
No statistical differences 
to the thinned skull 
window 
(see fig. 3.17 for further 
details) 
 
Statistical significance was determined by the Man Whitney test. 








Figure 3.17 Establishment and comparison of two cranial window types for two-photon live imaging of 
effector T cell motility behaviour in brain leptomeninges. Two cranial windows for intravital 2P-LSM were 
established and tested for their functionality and short-term influence on effector T cell motility behaviour. (A) 
The less invasive thinned skull window is limited in imaging depth. An imaging z-stack of brain leptomeninges 
was acquired through the thinned skull window. The z- stack was analysed with the Imaris software. Picture 1 
(upper row, level -0 μm) shows the top view of the z-stack (blue, bone + dura mater (second harmonic 
generation signal); red, underlying dural vessels and leptomeningeal vessels; green, TMBP-GFP cell infiltrates). In 
picture 2 (upper row, level -40 μm) the bone was virtually removed by cutting off the upper layers of the z-stack 
(red, dural vessels (bright red signal) and underlying leptomeningeal vessels (pale red); green, TMBP-GFP cell 
infiltrates). In addition, in picture 3 (upper row, level -60 μm) the dura mater was virtually removed by further 
cutting off the upper levels of the z-stack. The leptomeningeal vessels are only visible in pale red (green, TMBP-
GFP cell infiltrates). In the bottom row a 3D picture of the imaging stack was constructed. The deeper portion of 
the leptomeningeal vessels and deeper T cell infiltrates are not displayed because of insufficient imaging depth. 
(B) 3D reconstructions of brain and spinal cord after open window preparation. The open skull window allows 
the display of descending leptomeningeal vessels and deeper TMBP-GFP cell infiltrates. The three-dimensional 
reconstruction of the SC was adapted from (Bartholomäus et al., 2009). Blue, second harmonic generation 
signal; red, blood vessels stained by Dextran Texas Red; green, TMBP-GFP cell infiltrates; GFP, green fluorescent 
protein. (C) Comparison of the motility parameters track speed and track straightness of extravasated T cells 
imaged through the thinned skull and open skull cranial window. The displacement of tracked cells divided by 
the path length is indicated as straightness (a value of one means completely straight and directed movement). 
Dots represent the average value of individually tracked cells. Lines indicate the average value of all tracked 
cells. Data include the analysis of 17 or 18 TMBP-GFP cells. Statistical significance was determined by the Man 
Whitney test. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.  
 
3.9.2 Motility behaviour of effector TMBP-GFP and TβSyn-GFP cells in brain and SC 
leptomeninges 
In order to characterize the motility behaviour of effector T cells reactive against either 
myelin or neuronal antigen in the leptomeninges of brain and SC during ptEAE, both 
compartments were imaged in three dimensions by 2P-LSM over time. An example of the 
track analysis of GFP-positive effector T cells is shown for TβSyn-GFP cells in the 






Figure 3.18 Real-time imaging of the motility behaviour of effector TβSyn-GFP cells in the brain 
leptomeninges. 3D time-lapse movies were acquired via intravital 2P-LSM during the preclinical (A-B) and 
clinical phase (C-D) of EAE induced by i.v. transfer of TβSyn-GFP cells. Each movie was recorded for 32 min and 
analysed by the Imaris software. Green, TβSyn-GFP cells; red, leptomeningeal vessels labelled by i.v. injection of 
Dextran Texas Red; white, extravasated T cell trajectories; yellow, intraluminal T cell trajectories. Note that the 
first incoming TβSyn-GFP cells (A) are located exclusively in the leptomeningeal vessels where they show a 
crawling (yellow trajectories) or a rolling behaviour (single green dots, arrow). Some hours later a part of the 
cells starts to extravasate (B, white trajectories). At the beginning of the clinical symptoms (C) most of the 
effector T cells are extravasated. Some hours later the number of extravasated T cells increased drastically (D). 
Scale bar: 50 μm. 
 
3.9.3 Analysis of the motility behaviour of effector TMBP-GFP and TβSyn-GFP cells during 
the intraluminal phase 
Previous studies of our group showed that in ptEAE effector TMBP-GFP cells display a 




onset of the disease. The effector T cells crawl along the intraluminal surface of the blood 
vessels (72 % of intraluminal cells) before extravasation. Only a minor fraction of 
intraluminal T cells (28 %) roll along the vessel wall (fig. 3.19 A and Bartholomäus et al., 
2009). In order to assess whether this behaviour is specific for effector T cells in 
leptomeningeal vessels of the SC or in general hold true in any CNS compartment during 
MBP-induced ptEAE, the intraluminal crawling behaviour of TMBP-GFP cells in brain 
meningeal vessels was analysed. MBP-specific T cells, which arrive in the leptomeningeal 
vessels, show the typical vessel-associated crawling behaviour. Quantification of rolling and 
crawling effector TMBP-GFP cells in the subarachnoidal vessels of the brain revealed that rolling 
T cells (59 %) outnumber crawling T cells (41 %) (fig. 3.19 A).  
Subsequently, the motility behaviour of the intraluminal TMBP-GFP cells was compared to the 
one of TβSyn-GFP cells. Interestingly, in animals affected by βSyn-induced ptEAE most of the 
effector T cells were rolling (77 % or 87 %) in the subarachnoidal vessels both in the brain 
and the SC. Only 23 % (brain) or 13 % (SC) of effector T cells crawled along the blood vessel 
wall (fig. 3.19 B). In the early intraluminal phase (fig. 3.18 A) the rolling T cell phenotype 
was more pronounced than in the late intraluminal phase (indicated in fig. 3.18 B, 
quantification not shown).  
 
 
Figure 3.19 Quantification of rolling and crawling effector T cells within CNS leptomeningeal vessels. 
TMBP-GFP cells and TβSyn-GFP cells were used to induce ptEAE in Lewis rats. The leptomeninges of the brain and 
the SC were imaged during the intraluminal phase of effector T cells (just before disease onset) via 2P-LSM. 
The bar diagrams show the percentage of TMBP-GFP cells (A) or TβSyn-GFP cells (B) rolling (black) or crawling 
(grey) in the vascular beds of brain and SC leptomeninges. The number of analysed cells is indicated at the top 
of the bars. (Data in (A) (right bar) were kindly provided by Christian Schläger, Department of 





3.9.4 Analysis of the intraluminal crawling phenotype of TMBP-GFP cells and TβSyn-GFP 
cells in the leptomeningeal vessels of brain and SC. 
In order to learn if different crawling characteristics could justify the different pattern of 
inflammation that was observed, the crawling behaviour of TMBP-GFP and TβSyn-GFP cells was 
analysed in the meningeal vessels of brain and SC at the onset of the clinical symptoms (fig. 
3.20). In the brain meninges a generally low number of intraluminal TMBP-GFP cells was 
detected (fig. 3.22 A). The MBP-specific T cells in the leptomeningeal vessels of the brain 
crawled at a higher speed and more straight along the vessel wall than the ones in the SC (fig. 
3.20 A).  
During TβSyn-GFP cell-induced ptEAE more T cells were detected in brain meninges compared 
to MBP-induced EAE at the onset of the disease (fig. 3.22 A and fig. 3.23 A). Similar to what 
was observed for MBP-specific T cells, TβSyn-GFP cell trajectories were straighter in the brain 
vessels than in the SC, but the cell speed in the two compartments was similar (fig. 3.20 B 
and tab. 3.3). Finally, we compared the crawling parameters of MBP- and βSyn-specific T 
cells in the vessels of the two CNS compartments: No differences in the analysed parameters 
were detectable in the brain meningeal vessels, whereas TMBP-GFP cells were faster and 





Figure 3.20 Crawling behaviour of intraluminal TMBP-GFP and TβSyn-GFP cells in the leptomeningeal vessels 
of the brain and the SC at the onset of inflammation. EAE was induced by transfer of TMBP-GFP cells or TβSyn-
GFP cells to Lewis rats. Intraluminal crawling of the effector T cells in CNS vessels was imaged via 2P-LSM. 
Paths of the T cells were tracked. The locomotion parameters track speed and track straightness are shown. The 
displacement of tracked cells divided by the path length is indicated as straightness (a value of 1 means 
completely straight and directed movement). Dots represent the average value of individually tracked cells. 
Lines indicate average value of all tracked cells. Data include the analysis of 48 and 36 TMBP-GFP or 169 and 54 
TβSyn-GFP cells in the brain and spinal cord, respectively. T cells from three independent experiments were 
included in the analysis. Statistical significance was determined by the Man Whitney test. ns, not significant; *P 
< 0.05, **P < 0.01, ***P < 0.001, ****P < 0.  
 
Table 3.3 Comparison of motility parameters of intraluminal TMBP-GFP and TβSyn-GFP cells in the CNS 
compartments at disease onset 
 Brain (meninges) 
 
Significance SC (meninges) Significance 
































Mean ± s.d. are shown. Statistical significance was determined by the Man Whitney test. ns, not 
significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0. 
 
3.9.5 Motility behaviour of motile extravasated effector TMBP-GFP and TβSyn-GFP cells in 
the leptomeninges 
After diapedesis TMBP-GFP cells mainly crawl on the abluminal surface of the leptomeningeal 
vessels getting in contact with perivascular phagocytes. Later they diffusely infiltrate the 
meningeal area (Bartholomäus et al., 2009). In order to investigate if the same step-wise 
invasion was detectable in TβSyn-GFP cells, their distribution in the leptomeningeal areas was 
analysed by 2P-LSM during ptEAE (fig. 3.23 B). Similar to TMBP-GFP cells (fig. 3.22 B), TβSyn-
GFP cells accumulated in the perivascular areas of the SC vessels just after extravasation and 
some hours later they spread all over the meningeal plane (fig. 3.23 B right picture). 
Surprisingly, the perivascular phase was never observed in the leptomeningeal area of the 
brain independently of T cell antigen-specificity. This might be due to the lack of perivascular 




vessels (fig. 3.22 B left picture and 3.23 B left picture). A clear quantitative difference 
between the two cells types was observed: infiltration of TMBP-GFP cells into the 
leptomeningeal area during ptEAE was low in the brain and very pronounced in the SC (fig. 
3.22 C). During βSyn-induced ptEAE a dominant infiltration into brain leptomeninges was 
detected (fig. 3.23 C).  
The motility pattern of non-vessel-associated motile effector T cells in the leptomeningeal 
areas of the brain and SC was analysed. Effector T cells of both specificities move with 
similar speed in both compartments of the CNS at all analysed time points (fig. 3.21). When 
the meningeal infiltration increased, TβSyn-GFP cells virtually disappeared from the 
leptomeninges and could be found in the parenchyma (fig. 3.24). TMBP-GFP cells remained in   
the brain leptomeninges during the entire ptEAE course. 
 
Table 3.4 Comparison of motility parameters of extravasated TMBP-GFP and TβSyn-GFP cells in the CNS 
compartments at disease onset 
 Brain (meninges) 
 
Significance SC (meninges) Significance 
































Mean ± s.d. are shown. Statistical significance was determined by the Man Whitney test. ns, not 








Figure 3.21 Crawling behaviour of motile extravasated TMBP-GFP and TβSyn-GFP cells in the leptomeningeal 
area of brain and SC. EAE was induced by transfer of TMBP-GFP cells or TβSyn-GFP cells to Lewis rats. The 
crawling of extravasated effector T cells was imaged via 2P-LSM. Afterwards the T cell paths were tracked. The 
locomotion parameters track speed and track straightness are shown for TMBP-GFP cells (A) and TβSyn-GFP cells (B). 
The displacement of tracked cells divided by the path length is indicated as straightness (a value of 1 means 
completely straight and directed movement). Dots represent the average value of individually tracked cells. 
Lines indicate average value of all tracked cells. T cells from several independent experiments were included in 
the analysis and the total number of analysed cells is indicated for each graph. Statistical significance was 
determined by the Man Whitney test (upper graphs) or the Kruskal-Wallis test (lower graphs). ns, not significant; 







Figure 3.22 Time-lapse analysis of TMBP-GFP cell invasion in the leptomeninges of the CNS. Overview 
pictures composed of individual z-stack scans of the meninges of the parietal cortex (left) and the dorsal SC 
(right) acquired by intravital 2P-LSM. Red thread-like structures, dural and leptomeningeal vessels of the brain 
(left) and leptomeningeal vessels of the SC (right) labelled by intravenous injection of Dextran Texas Red; red 
dots, APCs labelled by intrathecal injection of Dextran Texas Red; green, TMBP-GFP cells. (A) At the onset of 
meningeal inflammation effector T cells enter the leptomeningeal vessels. The number of invading effector T 
cells is much higher in SC vessels (right) compared to brain vessels (left). (B) After an intraluminal phase 
effector T cells extravasate and accumulate at the abluminal side of leptomeningeal vessels of the dorsal SC. 
They can be found in close proximity to perivascular APCs (right). In the parietal cortex T cells extravasate and 




of the dorsal SC harbour a massive number of effector TMBP-GFP cells (right). In the same phase the number of 
effector TMBP-GFP cells is remarkably lower in the leptomeninges of the parietal cortex (left). Scale 100 μm. 
 
 
Figure 3.23 Time-lapse analysis of TβSyn-GFP cell invasion in the leptomeninges of the CNS. Overview 
pictures composed of individual z-stack scans of the meninges of the parietal cortex (left) and the dorsal SC 
(right) acquired by intravital 2P-LSM. Red thread-like structures, dural and leptomeningeal vessels of the brain 
(left) and leptomeningeal vessels of the SC (right) labelled by intravenous injection of Dextran Texas Red; red 
dots, APCs labelled by intrathecal injection of Dextran Texas Red; green, TβSyn-GFP cells. (A) At the onset of 
meningeal inflammation effector T cells are predominantly located in the leptomeningeal vessels. The number of 




phase effector T cells extravsate and accumulate at the abluminal side of leptomeningeal vessels of the dorsal 
SC. They can be found in close proximity to perivascular APCs (right). In the parietal cortex T cells extravasate 
and directly start to invade the leptomeninges. Perivascular APCs are lacking (left). (C) At the peak of the 
disease the leptomeninges of the parietal cortex are infiltrated massively by effector TβSyn-GFP cells (left). At the 
same time point in the disease, the number of effector TβSyn-GFP cells seemed to be lower in the leptomeningeal 
areas of the dorsal SC (right). Scale 100 μm. 
 
 
Figure 3.24 Effector TβSyn-GFP cells migrate deeper into the leptomeningeal area during meningeal 
inflammation.  A z-stack of scans of the parietal cortex leptomeninges was acquired via intravital 2P-LSM and 
reconstructed in 3D. TβSyn-GFP cells have started to migrate from the superior level of the leptomeningeal area to 
the parenchyma. Some TβSyn-GFP cells passed the layer of leptomeningeal APCs and reached an infiltration depth 
of 170 μm. Blue, dura mater (second harmonic generation signal); green, TβSyn-GFP cells; red, APCs labelled by 





3.10 Direct visualisation of the activation of effector T cells in situ at single 
cell level 
In order to investigate if the re-activation of the antigen-specific T cells could also take place 
deep in the CNS parenchyma, TMBP and TβSyn cells, which express the regulatory subunit of 
the transcription factor “nuclear factor of T cell activation” (NFAT) together with YFP were 
used to detect T cell activation. Dr. Lodygin (Department of Neuroimmunology, Institute for 
Multiple Sclerosis Research, University of Göttingen) established a NFAT-sensor and MBP-
specific T cells expressing NFAT-YFP (TMBP-NFAT-YFP cells). He demonstrated in vitro that the 
translocation of YFP-labelled NFAT occurs shortly after T cell activation. A nuclear NFAT 
signal was already detectable 3 min after the activation of the T cells with anti-rat-CD3 
antibodies in vitro (Lodygin et al., in press). Ex vivo quantification of TMBP-NFAT-YFP cells with 
nuclear NFAT isolated from the SC of a ptEAE-affected animal was carried out by Dr. 
Lodygin while TMBP-NFAT-YFP cell activation events in the brain of these animals were 
quantified as part of this thesis. Moreover, βSyn-specific TNFAT-YFP cells were established and 
tested in vitro for the effective translocation of NFAT-YFP after activation with APCs and the 
βSyn peptide. Already 1 h after the start of the co-culture an increase in the number of TβSyn-
NFAT-YFP cells with nuclear NFAT was detected (fig. 3.25 A and B). After 2-3 h the highest 
level of NFAT translocation was detected (approx. 70-80 % of TβSyn-NFAT-YFP cells showed a 
nuclear YFP signal). After a plateau phase a decrease in TβSyn-NFAT-YFP cells containing nuclear 










Figure 3.25 Direct visualization of effector TMBP-NFAT-YFP or TβSyn-NFAT-YFP cell activation in vitro and ex vivo 
at single cell level. (A and B) TβSyn-NFAT-YFP cells were incubated with APCs and re-stimulated with the TβSyn 
peptide. After 0, 0.5, 1, 2, 3. 6, 18, 24 and 36 h T cells were fixed and the cell nuclei were stained with DAPI. 
TβSyn-NFAT-YFP cells were analysed by fluorescence microscopy. (A) Representative time points 0, 3, 18 and 24 h 
after re-stimulation are shown. In the control situation (0 h after re-stimulation) most T cells showed a cytosolic 
NFAT-YFP signal while the nuclei are NFAT-YFP-negative. 2 and up to 3 h after re-stimulation, the highest 
number of T cells with nuclear NFAT-YFP was detected. Afterwards, the number decreased again (18 and 24 h). 
Scale bars: 10 μm. (B) Number of T cells with nuclear NFAT were counted and are shown in a bar diagram as 
percentage of TβSyn cells with nuclear NFAT. Not trans (NFAT not translocated), grey bars; trans (NFAT 
translocated), black bars). On the top of the bars the number of analysed cells is indicated. (C) Histological 
analysis of TMBP-NFAT-YFP cell and TβSyn-NFAT-YFP cell activation during ptEAE in brain and SC tissue. Number of 
TMBP-NFAT-YFP cells or TβSyn -NFAT-YFP cells with nuclear NFAT were counted in WM or GM respectively and are 
shown in a bar diagram as percentage of cells with nuclear NFAT. Total number of TMBP-NFAT-YFP cells analysed: 
onset: brain n = 392, SC n =313, peak: brain n = 456, SC n = 274; Total number of TβSyn-NFAT-YFP cells analysed: 
onset: Brain n = 497, SC n = 556, peak: Brain n = 1154, SC n = 699. 
 
Furthermore, TβSyn-NFAT-YFP cells were used in vivo to induce βSyn-specific ptEAE. After 
transfer of TβSyn-NFAT-YFP cells to Lewis rats, the animals developed a monophasic paralytic 
disease similar to the one observed after transfer of TβSyn-GFP cells (data not shown and fig. 3.3 
C) and the effector T cells exhibited a similar CNS homing pattern (data not shown). For 
further analysis, TMBP-NFAT-YFP and TβSyn-NFAT-YFP cell-injected animals were sacrificed at the 
onset and peak of the disease. Brain and SC tissue sections of these animals were examined 
for NFAT translocation events. It was previously shown in this thesis that the infiltration of 
βSyn-specific T cells in the CNS parenchyma is limited to GM areas and MBP-specific T 
cells mainly infiltrate the WM of the brain (see chapters 3.3 and 3.4). Therefore, the analysis 
of NFAT translocation in the effector T cells was limited to these areas of interest. Effector 
TβSyn-NFAT-YFP cells showed a higher percentage of nuclear NFAT at the onset (approx. 8.3 % 
in the brain and 8.6 % in the SC) compared to the peak of the disease (approx. 4.2 % in the 
brain and 2.4 % in the SC) in brain and SC grey matter (fig. 3.25 C). Effector TMBP-NFAT-YFP 
cells showed a similar percentage (approx. 16.3-20.9 %) of T cells with nuclear NFAT at the 
onset and peak of the disease in brain and SC white matter. During TβSyn-GFP cell-induced 
ptEAE the percentage of T cells containing nuclear NFAT was generally lower compared to 







4.1 Characterisation of infiltration pattern and tissue distribution of 
encephalitogenic T cells in GM and WM of different milieus of the CNS 
The aim of this thesis was to analyse the autoimmune responses in distinct milieus of the CNS 
and to determine the crucial factor(s) for the homing pattern of effector T cells specific for 
either grey or white matter antigens into the target organ.  
The neuronal antigen β-synuclein93-111 peptide (βSyn) and the classical myelin antigen MBP 
were tested for their potential to induce EAE. For this purpose, Lewis rats were immunized 
with MBP or βSyn in complete Freund´s adjuvant. Independently which antigen was used 
immunized animals developed an EAE with “classical” paralytic disease symptoms, i.e. 
ascending paresis paralysis (fig. 3.1). In order to investigate the specific role of effector T 
cells reactive against myelin or neuronal antigens, TMBP-GFP cells and TβSyn-GFP cells were 
established and tested in vivo and in vitro. Both T cell lines were specific for their appropriate 




 T cell phenotype and up-regulated the 
surface activation markers OX40 and IL-2R after re-stimulation (fig. 3.2 A and 3.3 A). When 
tested in vivo all TMBP-GFP cell transferred animals and the vast majority of TβSyn-GFP cell 
transferred animals developed a paralytic monophasic disease with similar disease severity 
(fig. 3.2 C and 3.3 C). In most TβSyn-GFP cell transferred animals a delay in disease onset and a 
faster recovery was observed. Due to the fact that β-synuclein is expressed by neurons, it 
seems possible that after βSyn-specific ptEAE-induction animals might suffer from different 
neurological symptoms in addition to classical EAE symptoms. In the literature βSyn is 
described as the only one of 70 CNS-associated new candidate peptides that was able to 
induce an EAE-like phenotype in Lewis rats after immunization with the peptide or transfer of 
non-labelled βSyn-specific T cells (Mor and Cohen, 2006). This was quite surprising 
considered that β-synuclein lacks a signal peptide and therefore it is considered to be a 
cytosolic protein (George, 2002). Because neurons themselves do not express MHC class II 
molecules it remains unclear how the β-synuclein antigen is presented to CD4-positive T 
cells. Recently it has been shown that -synuclein, a related member of the same protein 
family with similar protein structure can be secreted in vitro and in vivo (Emmanouilidou et 
al., 2010; 2011); no similar experimental evidence is reported for -synuclein. In two of the 
three published studies the induction of EAE with βSyn required a boosting pre-treatment of 




BBB or treated with cyclophosphamide, which enhances the autoimmune response prior to 
immunization (Kela-Madar et al., 2009; Mor et al., 2003). Uncommon cases of EAE were not 
described. In contrast to previous studies βSyn-specific EAE in this thesis was evoked 
without pre-treatment. Generally, a classical ascending paralysis was observed. It came as a 
surprise, though, that 4 animals (of the 139 clinically examined) developed a very uncommon 
disease phenotype that included upper limb paralysis or hemiparesis. It cannot be excluded 
that the occurrence of further uncommon symptoms was under-estimated. The clinical 
analysis was limited to motor symptoms that in the rats are generally ascribed to subcortical 
or SC lesions due to the lack of monosynaptic excitatory cortico-motoneuronal connections 
(Alstermark et al., 2004). No testing of cortical functions was performed.  
None of the three published β-synuclein studies analysed the pathophysiological background 
of βSyn-mediated EAE in detail. Mor et al. were mainly focussing on the induction of an 
EAE-like phenotype in the experimental animals, the analysis of disease symptoms and the 
characterisation of EAE-inducing T cells in vitro (Mor et al., 2003; Mor and Cohen, 2006). In 
addition, the authors showed inflammatory infiltrates in the SC and cerebral cortex of βSyn-
immunized animals, but no further detailed analysis was published (Mor et al., 2003). Kela-
Madar et al. confirmed the encephalitogenicity of a similar βSyn peptide including the amino 
acids 92-110 and showed that the immune response to the neuronal antigen can lead to T- and 
B-cell-mediated autoimmune spreading to epitopes of other neuronal but also myelin antigens 
(Kela-Madar et al., 2009). In the present study, a detailed analysis of the homing behaviour of 
both TMBP-GFP cells and TβSyn -GFP cells during the different ptEAE phases was performed.  
Antigen specificity did not influence the effector T cell homing behaviour during the 
preclinical phase in the peripheral tissues. As previously described for TMBP-GFP cells (Odoardi 
et al., 2012) TβSyn-GFP cells first entered the lung and then peaked in spleen and blood just 
before entering the CNS tissues.  
The homing pattern of TMBP-GFP cells and TβSyn -GFP cells in the CNS tissues was analysed by 
using 3 different parallel approaches: flow cytometry, 2P-LSM and histology. Histological 
analyses were performed on decalcified samples in order to keep the meninges intact. 2P-
LSM and histological data revealed that TMBP-GFP cells infiltrated the brain meninges in lower 
numbers than SC meninges (fig. 3.6 A-C and 3.7 A and B, fig. 3.22); instead flow-cytometry 
analysis revealed similar numbers of invading TMBP-GFP cells in both compartments (fig. 3.5 
A). It might be reasonable to assume that the T cell number in brain meninges was 
overestimated during ex vivo analysis due to anatomical differences between the 2 




an outer or endosteal layer, closely connected together. Instead the spinal dura mater forms a 
loose sheath around the medulla spinalis: even if it is separated from the arachnoidea by a 
potential cavity, the subdural cavity, the two membranes are, in fact, in strict contact. As a 
consequence, during the preparation the cranial dura mater, which contributes significantly to 
the total meningeal weight, but is only poorly infiltrated by T cells, was removed when the 
skull was opened. On the other hand, the spinal dura mater, also poorly infiltrated by T cells, 
was not separated from the leptomeninges.  
As expected, in the SC parenchyma the number of TMBP-GFP cells was higher than in brain as 
shown both by histology and flow cytometry (fig. 3.8 A, D and E and fig. 3.9 A-C, fig. 3.5 
A). This is in line with the general observation that in EAE the brain tissue is less infiltrated 
by TMBP-GFP cells and shows lower inflammation (Cross et al., 1993; Pender et al., 1995).  
Interestingly, analysis of CNS tissue revealed that TβSyn-GFP cells entered the brain in higher 
number than TMBP-GFP cells do (fig. 3.8); moreover, the number of infiltrating cells was similar 
in brain and SC parenchyma (fig. 3.5).  
Several different entry routes of effector T cells in the CNS have been postulated (Ransohoff 
et al., 2003). According to recent data the choroid plexus could play an important role for 
effector T cell entry. Indeed in the mouse model, TH17 cells were postulated to initiate EAE 
by entering through the choroid plexus via the CCR6-CCL20 axis (Reboldi et al., 2009). In 
our model the choroid plexus seemed to be irrelevant for effector T cell entry into the brain, 
because no TGFP cells were found in the plexus epithelium at any time point independently 
from the antigen specificity (fig. 3.6 D and I or 3.8 D and I). It has been previously shown by 
our group that both in rat and in mouse ptEAE, effector TMBP-GFP cells enter the SC tissue 
through the leptomeningeal vessels (Bartholomäus et al., 2009). Histological analysis of 
decalcified cryo-sections of animals transferred with MBP- and βSyn-specific T cells revealed 
that both of these cell types used the same infiltration route into brain parenchyma: at disease 
onset GFP-positive effector T cells entered the meninges and partially the underlying brain 
parenchyma. Interestingly, TβSyn-GFP and TMBP-GFP cells seemed to use different entry sites in 
the SC: while white matter antigen-specific TMBP-GFP cells as expected entered from the entire 
surrounding meninges, TβSyn-GFP cells were mainly found in the meninges adjacent to the 
dorsal horn (fig. 3.7). Moreover, the cells were located in deep grey matter mainly around 
parenchymal vessels. Hence the grey matter parenchyma was likely infiltrated directly by 
these cells.  
At the peak of the disease, only few TMBP-GFP cells were found in the brain parenchyma and 




D and E). In contrast, at the same time point massive TβSyn-GFP cell infiltrates were located in 
the sub-pial area and deep in the cortical grey matter (fig. 3.8 G and H). As expected, in the 
SC TMBP-GFP cells (Kawakami et al., 2005b; Bartholomäus et al., 2009) were distributed not 
just in the white matter but also in the grey matter; whereas TβSyn-GFP cells infiltrated almost 
exclusively the grey matter at the peak of the disease.  
To my knowledge, the specific and massive distribution of effector TβSyn-GFP cells in the grey 
matter is unique. Cortical infiltration and preferential involvement of the grey matter are rare 
in EAE models where the infiltration in general is localized in the SC and mainly in the white 
matter (Linker and Lee, 2009). The described active EAE models are less suitable to 
investigate the role of the effector T cells responsible for disease pathogenesis because they 
do not allow the tracking of the pathogenic effector T cells (Pomeroy et al., 2005; Storch et 
al., 2006; Huizinga et al., 2008). One of these cortical EAE models is the focal EAE model 
described by Merkler (Merkler et al., 2006b). In contrast to this study the cortical infiltrations 
in the present study were not evoked by exogenous manipulation after EAE induction. To my 
knowledge only one model of passive transfer EAE has been described. In this model, T cells 
reactive against the neuronal antigen TAG-1 were used for disease induction (Derfuss et al., 
2009). The inflammatory infiltrates found in this study were localized in both white matter 
and grey matter but they were limited to the perivascular areas.  
The cortical effector T cell infiltrations in βSyn-induced ptEAE observed in this study 
resembled the infiltrates found in cortical lesions of early and moreover primary progressive 
multiple sclerosis patients (Lucchinetti et al., 2011; Choi et al., 2012). Similar to these 
patients, animals affected by βSyn-specific ptEAE show marked but diffuse meningeal and 
perivascular meningeal, but also sub-pial infiltration of T cells, which spreads intracortically. 
Further analysis of CNS tissue will reveal whether secondary recruited inflammatory cells and 
T cell-induced tissue damage are prominent in this ptEAE model. 
  
4.2 Analysis of the mechanisms that determine effector T cell infiltration 
and distribution in GM and WM of different CNS milieus 
Histological analysis showed that the antigen specificity of effector T cells is important for 
entry site and distribution of these cells within the CNS. Both tissue-intrinsic properties and 
cell-dependent factors could justify this observation.  
The CNS parenchyma has been described as an immune hostile milieu that induces rapid 




detected by anti-active Caspase-3 antibody staining of both TMBP-GFP and TβSyn-GFP cells was 
low at all the examined time points and in all the analysed tissues. Even if there was a general 
mild increase of apoptosis rate at the peak of the disease, no main differences between the 
CNS compartments were detected at the same time point.  
It is well-known that chemokines play a key role in the immune system by directing the 
trafficking of immune cells in the different tissues both in a healthy state as well under 
inflammatory condition (Bromley et al., 2008). It was demonstrated that transmigration of 
effector T cells across the BBB is chemokine-dependent and therefore the 
chemokine/chemokine receptor pathway plays an important role in T cell homing into the 
CNS (reviewed in Holman et al., 2011). CCL19 could be detected by in situ hybridization at 
the level of the BBB (Alt et al., 2002). In our system the expression of CCL19 was detectable 
at very low levels in the meninges of brain and SC by QRT-PCR, but there were no 
remarkable differences between these two compartments (data not shown). Also the 
expression of the homeostatic chemokine CXCL12 and the pro-inflammatory chemokines 
CCL5, CXCL9, CXCL10, and CXCL11 in the CNS was analysed via QRT-PCR in naïve 
animals and during the EAE course. The expression levels of all these chemokines but 
CXCL12 were very low in naïve animals in all the CNS compartments and increased during 
the inflammation mirroring the effector T cell infiltration pattern. Conversely, CXCL12 
expression was very high in the non-inflamed meningeal tissue both in brain and SC and was 
down-regulated during inflammation (fig. 3.11). CXCL12 is known to be expressed 
constitutively in the CNS, especially by endothelial cells of the CNS vasculature  (Stumm et 
al., 2002; Krumbholz et al., 2006). Under non-inflamed conditions this signalling molecule is 
expressed on the parenchymal surface of CNS endothelial cells and seems to function by 
repelling CXCR4-expressing leukocytes from the BBB (McCandless et al., 2006; 2008a; 
2008b). In MS and EAE re-distribution of CXCL12 from the abluminal side of the CNS 
microvasculature towards the luminal side was shown (McCandless et al., 2008a; 2008b; 
Cruz-Orengo et al., 2011). The alteration in the CXCL12 expression correlated with disease 
severity (McCandless et al., 2008a) and was associated with leukocyte entry (McCandless et 
al., 2006). However, even if the observed down-regulation of the T cell repellent CXCL12 
might promote the entry into the CNS of MBP- or βSyn-specific effector TGFP cells the very 
similar expression of this molecule in both the meningeal compartments does not justify the 





Alternatively, the distinct tissue distribution of TMBP-GFP and TβSyn-GFP cells could be due to 
cell-intrinsic properties. Recently it has been shown that after transfer effector T cells have to 
undergo a complex re-programming of their expression profile by down-regulating their 
activation and proliferation program and up-regulating an appropriate set of surface molecules 
(i.e. chemokine receptors and integrins) in the peripheral organs. These phenotypic changes 
are necessary to allow the effector T cells to overcome the BBB (Odoardi et al., 2012). Just 
before entering the CNS TMBP-GFP or TβSyn-GFP cells isolated from blood showed a similar 
integrin and chemokine receptor expression profile and thereby had the same prerequisites to 
enter the CNS (fig. 3.12 A). The cells of both specificities strongly expressed VLA-4 which is 
necessary for effector T cells to first interact shortly with and later to firmly adhere to the 
vascular epithelial cells of the BBB (Berlin et al., 1995; Vajkoczy et al., 2001; Bartholomäus 
et al., 2009). LFA-1 expression was lower than VLA-4 expression in both cell types (fig. 3.12 
A).  
Regarding the chemokine receptor expression profile, a strong expression of CXCR3 and 
CXCR4 and a lower expression of CCR5, CCR6 by both effector T cell types was detected 
(fig. 3.12 A). Functional ex vivo transmigration analysis performed in parallel revealed that 
TMBP-GFP or TβSyn-GFP cells, purified from blood at the onset of the disease, showed a similar 
preferential chemoattraction to CCL20 (ligand of CCR6) and CXCL11 (ligand of CXCR3), 
whereas no directional movement versus CXCL12 (ligand of CXCR4) was observed (fig. 
3.12 B). The high expression level of CXCR3 in effector T cells is well documented. In 
several disease models it has been shown that this chemokine receptor plays an essential role 
in licensing T cell entry into the CNS (Groom and Luster, 2011). In particular in Lewis rat 
ptEAE it has been shown that CXCR3 blocking by specific monoclonal antibodies strongly 
reduces disease severity (Sporici and Issekutz, 2010). Also the CCR6/CCL20 axis has been 
involved in the recruitment of effector T cells at the beginning of the inflammation not just in 
the choroid plexus (Reboldi et al., 2009) but also in the spinal cord at the fifth lumbar 
vertebrae: the up-regulation of the CCL20 ligand at this SC level led to infiltration of auto-
reactive T cells in the area of chemokine expression (Arima et al., 2012). My data suggest that 
both these chemokine receptors and the VLA-4 integrin could play a major role in the initial 
effector T cell entry in the target tissue at the onset of the disease. However, the finding that 
TMBP-GFP and TβSyn-GFP cells show the same surface receptor expression pattern just before the 
entry in the target tissue indicated that other mechanisms determine the different CNS homing 
pattern of these cells. It was demonstrated that distinct expression of adhesion molecules and 




reason of the different topology of the lesions. Independently from the antigen specificity, the 
TGFP cells isolated from the different CNS compartments during on-going inflammation 
showed a very similar expression profile of these molecules and a preferential targeted 
migration towards CXCL11 and CCL20. Moreover, the expression of VLA-4 was higher than 
LFA-1 expression in T cells of both specificities (fig. 3.13 and 3.14). 
Finally, also the hypothesis that a different ratio between TH1 and TH17 cells may determine 
the site of infiltration in the CNS (Stromnes et al., 2008) could be reasonably excluded 
because TMBP-GFP and TβSyn-GFP cells showed a very similar cytokine expression profile before 
entering the CNS (fig. 3.16).  
 
By combining 2P-LSM and functional characterization it has been shown in a previous study 
that effector TMBP cells enter the SC via the meninges in a step-wise mechanism. The 
incoming cells first crawl extensively on the intraluminal leptomeningeal endothelium; after 
diapedesis they scan the outside surface of the vessel wall where they get in contact with local 
perivascular phagocytes, which are able to present the cognate antigen (Bartholomäus et al., 
2009). Consequently, as it was recently demonstrated in vivo by using a genetically encoded 
NFAT biosensor the T cells get locally re-activated in the leptomeninges (Lodygin et al., in 
press). The level of activation is essential for the T cellular invasion into the parenchyma and 
it is dependent on antigen availability (Kawakami et al., 2004). It is important to note that the 
motility parameters of effector T cells during the extravasation steps are related to their 
activation status: brain-ignorant TOVA cells that are not activated in the CNS tissues crawl 
faster and for shorter time in the leptomeningeal vessels compared to TMBP-GFP cells. 
Moreover, once extravasated they established shorter contacts with meningeal phagocytes. 
Based on this background I hypothesized that a different antigen distribution and therefore a 
different activation level could justify the observed divergent infiltration pattern of TMBP-GFP 
cells in brain and SC. In order to test this hypothesis, in vivo imaging of effector T cells in 
brain and SC meninges was performed. Whereas the optical window for accessing the lumbar 
SC had been already established (Odoardi et al., 2007; Bartholomäus et al., 2009), the access 
window to the parietal cortex had to be established and tested. Interestingly, from an 
anatomical point of view the two tissues visualized by 2P-LSM showed some remarkable 
differences: the 3D collagen network identified by second harmonic generation was much 
more prominent in the SC compared to the brain meninges (not shown). Moreover, whereas 
numerous local macrophages were detected around the SC meningeal vessels the same 




phagocyte distribution could justify why no perivascular accumulation of effector T cells was 
observed in any phase of the disease independently from the antigen-specificity and the level 
of infiltration (fig. 3.22 and 3.23, left pictures).  
2P-LSM imaging of living animals showed that the motility behaviour of effector TMBP-GFP 
cells in brain meninges was very different from the motility pattern of the same cells in the 
SC meninges: during the intravascular phase the percentage of TMBP-GFP cells crawling on the 
brain leptomeningeal vessels was lower than in SC vessels (41 % vs. 72 %); moreover, the T 
cells crawled faster (14.9 μm/min vs. 9.65 μm/min) and in a more straight way (0.66 vs. 0.42), 
suggesting a reduced activation of the local endothelium in the brain. After diapedesis the 
effector T cell velocity that is likely to be controlled by cell-intrinsic properties 
(Lämmermann et al., 2008) was similar in both meningeal compartments (10.7 μm/min vs. 
10.3 μm/min). Taken together, the motility data suggest a lower level of activation of effector 
TMBP-GFP cells in the brain meninges compared to the SC meninges. Consistent with the 
hypothesis that the activation level is critical for the further invasion in the parenchyma 
(Kawakami et al., 2005b), in all the investigated EAE phases the number of TMBP-GFP cells 
able to infiltrate the brain meninges was extremely low and no infiltration in the adjacent GM 
was detectable. The motility data were flanked by functional data. TMBP-GFP cells sorted from 
the meninges of both compartments showed a lower level of cytokine expression in the brain 
meninges compared to SC meninges (fig. 3.16 C). However, this data - even if consistent with 
the motility data - should be interpreted cautiously. 2P-LSM imaging of the brain was 
performed on the parietal cortex meninges that surmount grey matter regions whereas effector 
T cells were sorted from the total meninges that are in contact both with GM and WM areas. 
Therefore, in order to compare exactly the same meningeal compartment, assessment of the 
level of activation of TMBP cells has to be performed in situ by using the NFAT biosensor. 
 
Functional characterization and 2P-LSM analysis were also performed on TβSyn-GFP cells in the 
brain and SC meninges. In both CNS compartments, the level of activation of the sorted TβSyn-
GFP cells was higher than in the blood indicative of a local re-activation. For the first time the 
step-wise invasion of effector T cells directed against a neuronal antigen into the CNS tissue 
was visualized via 2P-LSM. The first incoming T cells in the leptomeningeal vessels of SC 
and brain meninges were mainly rolling (approx. 80 %) resembling the motility behaviour of 
TMBP-GFP cells in the brain leptomeningeal vessels. After diapedesis in the SC meningeal 
compartment TβSyn-GFP cells showed the typical perivascular localization before spreading on 




on the surface without showing a strict perivascular phase. With the on-going inflammation, 
TβSyn-GFP cells invaded in high numbers both of the meningeal compartments. Moreover, 2P-
LSM imaging in the brain parenchyma showed that the TβSyn-GFP cells penetrated deep in the 
grey matter at the peak of the disease (fig. 3.24). Local re-activation of TβSyn-GFP cells in the 
brain GM might license these cells to penetrate deeper into the parenchyma. As discussed for 
TMBP cells, more detailed investigation of the activation level of TβSyn cells in situ has to be 
performed by using the genetically encoded NFAT biosensor.  
 
Even if it is reasonable to think that T cells of both specificities use the meninges as main 
entry port, the histological data suggest that the meninges might not be the sole way of entry. 
At the onset of the disease TβSyn-GFP cells were localized not only in the meningeal area but 
also deep in the GM of the SC mainly around parenchymal vessels (fig. 3.7). Similarly, at the 
peak of the disease TMBP-GFP cells were localized deep in the WM of the brain (fig. 3.8 E). In 
both cases the availability of the antigen seemed to determine the topology of T cell 
infiltration. This observation was particularly evident in the SC of TβSyn-GFP cell transferred 
animals. It is known that in rodents the DRG express a high level of -synuclein whereas the 
perikarya of the SC motor neurons are largely devoid of this protein (Giasson et al., 2001). 
Accordingly, TβSyn-GFP cells were mainly localized in the posterior horns of the SC.  
In order to investigate if the re-activation of the antigen specific T cells could also take place 
deep in the parenchyma, TMBP and TβSyn cells, which express the regulatory subunit of the 
transcription factor NFAT together with YFP were used. NFAT activation is a very early 
event after TCR signalling; therefore translocation of NFAT from the cytosol to the nucleus 
allows monitoring in a spatial and temporal manner the process of activation. The results were 
clear: TMBP-GFP cells that underwent translocation were detectable in the WM of both SC and 
brain whereas successful translocation in TβSyn-GFP cells was detectable in the GM of the same 
compartments demonstrating a direct activation in the parenchyma. 








In this work histological analysis, two-photon imaging and functional characterization were 
combined to investigate the mechanisms that regulate the entry of effector T cells into 
different CNS compartments i.e. brain and SC meninges, brain and SC parenchyma. For this 
purpose, EAE was induced by passive transfer of TMBP-GFP cells or TβSyn-GFP cells in Lewis 
rats. Irrespective of their differing antigen specificity, both types of effector T cells exhibited 
the same expression profile in vitro and a similar pathogenic potential in vivo. However, a 
radically different infiltration pattern between TMBP-GFP and TβSyn-GFP cells was demonstrated 
by histological analysis: whereas the TMBP-GFP cells predominantly infiltrated the SC, in 
particular the white matter region, the TβSyn-GFP cells were distributed exclusively in grey 
matter regions of both brain and SC. Chemokine expression or apoptosis rate in the different 
CNS compartments as assessed by quantitative real-time PCR and active Caspase-3 staining 
did not seem to play a role. Gene expression analysis of chemokine receptors or integrins on 
TMBP-GFP cells and TβSyn-GFP cells isolated from the periphery during the preclinical phase and 
from the different CNS compartments during the clinical phase excluded that these proteins 
played a role in determining the observed differential cell distribution. The chemokine 
expression data were confirmed by ex vivo transmigration studies.  
In order to visualize the direct entry and distribution of the TMBP-GFP and TβSyn-GFP cells, life 
imaging by 2P-LSM was performed on the CNS meningeal compartments. As expected, 
TMBP-GFP cells invaded the meninges of the SC in high numbers whereas very few of them 
were visible in the brain meninges even at the peak of the disease. TβSyn-GFP cells at the onset 
of the disease invaded both the compartments in similar numbers. However, at the peak of the 
disease a massive infiltration of these cells was only detectable in the brain parenchyma, 
supporting the hypothesis that antigen-dependent activation of encephalitogenic T cells is the 
key factor that determines the distribution of these cells into the target tissue. Finally, by 
using a NFAT biosensor the in situ activation of TMBP in the white matter and of TβSyn cells in 
the grey matter was demonstrated. 
In my opinion the data have dual importance. From a scientific point of view it introduces a 
-synuclein transfer EAE model that makes it possible to study grey matter inflammation, an 
important aspect of MS pathology. Secondly, the data could be of clinical relevance: it is now 
well accepted that at least some MS patients already have inflammatory lesions in their CNS 
grey matter in the early phase of the disease. Based on my data I suggest that an anti-neuronal 
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